EP0012957B1 - Diagnostic means for the detection of proteolytic enzymes and indoxyl or thioindoxyl ester chromogens useful therefor, process for their preparation and their use in the preparation of diagnostic means - Google Patents

Diagnostic means for the detection of proteolytic enzymes and indoxyl or thioindoxyl ester chromogens useful therefor, process for their preparation and their use in the preparation of diagnostic means Download PDF

Info

Publication number
EP0012957B1
EP0012957B1 EP79105184A EP79105184A EP0012957B1 EP 0012957 B1 EP0012957 B1 EP 0012957B1 EP 79105184 A EP79105184 A EP 79105184A EP 79105184 A EP79105184 A EP 79105184A EP 0012957 B1 EP0012957 B1 EP 0012957B1
Authority
EP
European Patent Office
Prior art keywords
alanyloxy
indole
indol
sulfonyl
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP79105184A
Other languages
German (de)
French (fr)
Other versions
EP0012957A1 (en
Inventor
Dieter Dr.Rer.Nat. Berger
Franz Dr.Rer.Nat. Braun
Werner Dr.rer.nat. Güthlein
Manfred Dr.Rer.Nat. Kuhr
Wolfgang Dr.Rer.Nat. Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6057730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0012957(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Priority to AT79105184T priority Critical patent/ATE230T1/en
Publication of EP0012957A1 publication Critical patent/EP0012957A1/en
Application granted granted Critical
Publication of EP0012957B1 publication Critical patent/EP0012957B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • C12Q2334/50Indoles

Definitions

  • the object of the present invention was therefore to provide a diagnostic agent with which the leukocytes in body fluids can be detected in a simple and easy-to-use manner and as quickly and completely as possible.
  • British patent 11 28 371 describes and claims a diagnostic agent for the detection of hydrolytic enzymes in body fluids.
  • an absorbent carrier is impregnated with colorless indoxyl or thioindoxyl esters and optionally a buffer and an oxidizing agent.
  • free indoxyl or thioindoxyl is formed from the esters and from this deeply colored indigo or thioindigo by the action of atmospheric oxygen or oxidizing agent.
  • the compounds claimed in this patent are not useful for a leukocyte test because they show no reaction even at 10,000 leukocytes / ⁇ I.
  • Another object of the present invention is the use of indoxyl and / or thioindoxyl amino acid esters and / or peptide esters of the general formula for the preparation of diagnostic agents for the detection of proteolytic enzymes, in particular the proteases present in the leukocytes in body fluids.
  • the present invention therefore also relates to the indoxyl and thioindoxyl amino acid esters and peptide esters of the general formula I and processes for their preparation.
  • the new indoxyl and thioindoxyl amino acid esters and peptide esters of the general formula I can be prepared by methods known per se from peptide chemistry.
  • the corresponding indoxyl or thioindoxyl compounds of the general formula II are known in which R i , R 2 , R 3 , R 4 and X have the meaning given above, with amino acids and peptides of the general formula III in which A and B have the meaning given above, or with suitable reactive derivatives thereof.
  • reactive derivatives e.g. the acid chlorides, or the mixed anhydrides usually used in peptide synthesis, for example with ethyl chloroformate or active ester.
  • indoxyl and thioindoxyl compounds of the general formula II, as well as the amino acids and peptides of the general formula III are known substances (see, for example, P. Frieders, Advances in Tar Dye Manufacturing and Related Industries, Vol. 3-20 and Houben-Weyl, Methods of organic chemistry, Vol. 15/1), or can be prepared in analogy to known compounds.
  • Halogen in the definition of R 1, R 2 , R 3 and R 4 is to be understood as fluorine, chlorine, bromine and iodine, preferably chlorine and bromine.
  • the “lower alkoxy group” in the definition of R 1 , R 2 , R 3 and R 4 , and the “lower alkyl group” of R 1 , R 2 , R 3 , R 4 and X contain 1 to 5, preferably 1 to 3 Carbon atoms, with the methoxy and the methyl group being particularly preferred.
  • R i , R 2 , R 3 and R 4 and an “aralkyl group” in the definition of R 1 , R 2 , R 3 , R 4 and X are, for example, by oxy-lower
  • alkyl or lower alkyl radicals substituted phenyl and naphthyl groups the alkyl radical containing 1 to 5, preferably 1 to 3, carbon atoms.
  • the benzyloxy and the benzyl radical are particularly preferred.
  • the “lower acylamino group” of R i , R 2 , R 3 and R 4 are the amide groups of the lower aliphatic carboxylic acids having 1 to 5, preferably 1 to 3, carbon atoms.
  • the acetylamino radical is particularly preferred.
  • the “acyl radical” in the definition of X is the radicals of aliphatic carboxylic acids with 1 to 5, preferably 1 to 3, carbon atoms, or also aromatic carboxylic acids, such as, for example, benzoic or naphthoic acids. Acetyl and benzoyl radicals are particularly preferred.
  • aryl radical in the definition of R 1 , R 2 , R 3 , R 4 and X is preferably to be understood as the phenyl or naphthyl group.
  • amino acid residue in the definition of A is preferably the residues of the natural a-amino acids in their L or D form or also in their racemic form.
  • residues of glycine, alanine, valine, leucine, isoleucine, phenylalanine and tyrosine are particularly preferred. Any free hydroxyl groups present can be acylated, preferably acetylated.
  • peptide residue in the definition of A are e.g. To understand di-, tri-, tetra- and pentapeptides, preferably di- and tripeptides, the amino acid components mentioned preferably being used as the amino acid components.
  • nitrogen protecting group common in peptide chemistry is e.g. To understand acyl, oxycarbonyl, thiocarbonyl, sulfonyl, sulfenyl, vinyl, cyclohexenyl, phosphoryl or carbamoyl groups.
  • indoxyl or thioindoxyl amino acid esters and peptide esters of the general formula used according to the invention as chromogens are used in concentrations of 10 to 4 to 1 mol / liter, preferably 10 to 3 to 10 mol / liter of impregnating solution, coating composition or liquid to be examined.
  • Another component of the diagnostic agent for the detection of proteolytic enzymes and in particular the leukocyte proteases is a suitable buffer system.
  • the pH and capacity must be selected so that a pH of 6-10, preferably 7-9, is established in the measurement solution or on the test strip.
  • additional oxidizing agents can be used in order to convert the indoxyl or thioindoxyl compounds, which primarily result from the enzymatic reaction, to the colored indigo or thioindigo compounds. Implement substances.
  • oxidizing agents such as, for example, potassium hexacyanoferrate III, potassium bromate, potassium chromate, phenazine methosulfate or tetrazolium salts, are used in concentrations of 10 to 4 to 1 mol / liter, preferably 10 to 10 mol / liter, of impregnating solution, coating composition or liquid to be examined used.
  • a further component of a diagnostic agent for the detection of proteolytic enzymes, in particular leukocyte proteases, can be a wetting agent, since this results in somewhat shorter reaction times and sometimes. brilliant colors can be achieved.
  • Nonionic but also amphoteric, cationic or anionic wetting agents are preferably used in concentrations of 0.05-2%, preferably 0.1-1%.
  • the agent according to the invention e.g. absorbent carrier, preferably filter paper, cellulose or synthetic fiber fleece, with solutions of the necessary reagents (substrate, buffer, optionally wetting agent, oxidizing agent, etc.) usually used for the production of test strips in volatile solvents, such as e.g. Water, methanol, ethanol or acetone, impregnated.
  • volatile solvents such as e.g. Water, methanol, ethanol or acetone
  • the finished test papers can be used as such or glued to handles in a manner known per se or preferably sealed between plastics and fine-meshed networks in accordance with DBP 21 18 455.
  • a film-forming substance e.g. Polyvinyl ester or polyamide
  • the mixture is spread in a thin layer on a plastic carrier and dried.
  • the film-coated test strips according to the invention are cut after drying and can be used as such or glued to handles in a manner known per se or e.g. between plastics and fine-mesh networks according to DBP 21 18 455.
  • the diagnostic agent according to the invention for the detection of proteolytic enzymes, in particular the leukocyte proteases, in the form of powder mixtures or reagent tablets can be produced by adding the usual components of the test to the components of the test and granulating them.
  • Additives of this type are e.g. Carbohydrates, e.g. Mono-, oligo- or polysaccharides, or sugar alcohols, e.g. Mannitol, sorbitol or xylitol, or other soluble inert compounds such as polyethylene glycols or polyvinylpyrrolidone.
  • the powder mixtures or reagent tablets generally have a final weight of approximately 50-200 mg, preferably 50-80 mg.
  • a solution is freeze-dried which, in addition to all the Re Agents customary scaffolders, such as polyvinyl pyrrolidone, and possibly other fillers, such as mannitol, sorbitol or xylitol, contains.
  • customary scaffolders such as polyvinyl pyrrolidone, and possibly other fillers, such as mannitol, sorbitol or xylitol, contains.
  • the diagnostic agent according to the invention in the form of a solution preferably contains all the reagents required for the test.
  • a water-soluble organic solvent such as e.g. Methanol, ethanol, acetone or dimethylformamide
  • the diagnostic agents make it possible to quickly and easily detect the presence of proteolytic enzymes, in particular the leukocyte proteases, after immersion in the body fluid to be examined or after addition to the relevant body fluid, by color formation that can be visual or photometric, e.g. remission photometric or in the cuvette. Since the activity of the leukocyte proteases per cell can be regarded as an essentially constant variable, the leukocyte concentration of the examined body fluid can be determined from the intensity of the color formation. Both intact and lysed leukocytes are detected with the diagnostic agent according to the invention, since the activity of the leukocyte proteases is fully retained even after the leukocytes have been lysed. A lysis error therefore does not occur.
  • Filter paper eg Schleicher + Schüll 23 SL
  • Filter paper eg Schleicher + Schüll 23 SL
  • the sensitivity of the test is around 200 leukocytes / ⁇ l.
  • the assessment can also be carried out using reflectance photometry at 620 nm.
  • Filter paper eg Schleicher + Schüll 23 SL
  • Filter paper eg Schleicher + Schüll 23 SL
  • a yellow-colored test paper is obtained, which turns red when immersed in leukocyte-containing urine.
  • the sensitivity of the test is around 1000 leukocytes / ⁇ l urine.
  • the evaluation can also be carried out at 576 nm using reflectance photometry.
  • Example 1 The substrates of Example 1 are treated with oxidizing agents, such as, for example, the potassium hexacyano ferrate III used above, or e.g. with potassium bromate, potassium chromate, phenazine methosulfate or tetrazolium salts, test papers are obtained which, in part, compared to analog test papers without oxidizing agents. have slightly reduced response times.
  • oxidizing agents such as, for example, the potassium hexacyano ferrate III used above, or e.g. with potassium bromate, potassium chromate, phenazine methosulfate or tetrazolium salts
  • Filter paper eg Schleicher + Schüll 23 SL
  • Filter paper eg Schleicher + Schüll 23 SL
  • a colorless test paper is obtained, which changes color from light turquoise to blue when immersed in leukocyte-containing urine, depending on the concentration of leukocytes. Compared to the recipe of Example 1, the reaction times are somewhat shorter and the colors are slightly more brilliant.
  • wetting agents such as the nonylphenol polyglycol ether (nonionic) used above, but also e.g. with cocosimidazoline compounds (amphoteric) or benzyltrimethylammonium chloride (cationic) or sodium sulfonato-dodecylbenzene (anionic), obtained test papers, some of which are comparable to analog test papers without wetting agents. have slightly reduced response times and somewhat more brilliant colors.
  • the mixture gradually changes color - depending on the leukocyte concentration - from light green to deep blue.
  • the leukocyte concentration is determined visually using reference colors or photometrically, e.g. in 1 cm cuvettes at 620 nm.
  • the sensitivity of the test is around 200 leukocytes / ⁇ l urine.
  • Test tube or cuvette tests with similar sensitivities can also be carried out with the other substrates of Examples 1 and 2.
  • the urine is added to 2 ml of urine containing leukocytes in a test tube.
  • the urine gradually changes color - depending on the concentration of leukocytes - from light green to deep blue.
  • the leukocyte concentration is determined visually with the aid of reference colors or photometrically, e.g. in 1 cm micro cuvettes at 620 nm.
  • the sensitivity of the test is around 200 leukocytes / ⁇ l urine.
  • the reaction time can be shortened significantly if the incubation is carried out at 37 ° C.
  • Filter paper eg Schleicher + Schüll 23 SL
  • Filter paper eg Schleicher + Schüll 23 SL
  • a colorless test paper is obtained which turns blue when immersed in aqueous solutions which contain the proteolytic enzyme chymotrypsin. Concentrations of 0.02 U chymotrypsin per ml can be detected in about 6-7 minutes.
  • chymotrypsin or other proteolytic enzymes such as e.g. Elastase or trypsin
  • body fluids such as Detect whole blood, serum, cerebrospinal fluid, pancreatic secretions or watery stool extracts.
  • Solution 1 is poured into solution 2 and stirred with the exclusion of oxygen and water for about 5 h at -15 ° C. until no more indoxyl can be recognized by TLC.
  • the reaction mixture is concentrated in vacuo at a maximum bath temperature of 40-50 ° C.
  • the residue is taken up in 100 ml of ethyl acetate and successively twice with 30 ml of 1 N citric acid, 20 ml of water and 50 ml of 5 percent. Washed sodium bicarbonate solution and 25 ml of water.
  • the ethyl acetate phase is - after drying with sodium sulfate - evaporated in vacuo.
  • the deposited N, N'-dicyclohexylurea is filtered off with suction, the solvent is distilled off in vacuo and the residue is taken up in about 100 ml of ethyl acetate.
  • the clear ethyl acetate solution is in succession twice with 30 ml of 1 N citric acid, 20 ml of water, 50 ml of 5-10 percent. Washed sodium bicarbonate solution and 25 ml of water. After drying over sodium sulfate, the ethyl acetate phase is concentrated in vacuo.
  • the amorphous residue is purified by column chromatography on silica gel using a toluene / dioxane mixture (9: 1).

Description

Der Nachweis von Leukozyten in Körperflüssigkeiten, insbesondere im Urin, nimmt eine hervorragende Stelle in der Diagnostik der Erkrankungen der Niere und des Urogenitaltraktes ein.The detection of leukocytes in body fluids, especially in the urine, plays an outstanding role in the diagnosis of diseases of the kidney and urogenital tract.

Bisher wird dieser Nachweis geführt durch mühsames Auszählen der Leukozyten im nicht zentrifugierten Harn oder im Harnsediment.So far, this detection has been carried out by laboriously counting the leukocytes in the non-centrifuged urine or in the urine sediment.

Beiden Methoden ist naturgemäss gemeinsam, dass nur intakte Leukozyten erfasst werden. Andererseits ist bekannt, dass die Geschwindigkeit der Leukozyten-Lyse je nach Harnmilieu enormen Schwankungen unterworfen ist; so ist z.B. in stark alkalischen Harnen mit einer Leukozyten-Halbwertszeit von nur 60 Minuten zu rechnen. Zu niedrige Leukozytenzahlen bzw. bei längeren Harnstandzeiten sogar falschnegative Befunde sind die Folge.It is common to both methods that only intact leukocytes are recorded. On the other hand, it is known that the speed of leukocyte lysis is subject to enormous fluctuations depending on the urinary environment; for example In strongly alkaline urines, a leukocyte half-life of only 60 minutes can be expected. The result is low leukocyte counts or, in the case of long urine retention times, false negative results.

Vom Lyse-Fehler abgesehen, liefert die quantitative mikroskopische Bestimmung der Leukozyten im nicht zentrifugierten, homogenisierten Harn in der Zählkammer recht zuverlässige Werte. In der Praxis wird diese Methode jedoch nur selten angewandt, da sie mühevoll, ermüdend und zeitraubend ist und den Einsatz geschulten Personals bedingt.Apart from the lysis error, the quantitative microscopic determination of the leukocytes in the non-centrifuged, homogenized urine in the counting chamber provides quite reliable values. In practice, however, this method is rarely used because it is tedious, tiring and time-consuming and requires the use of trained personnel.

Die überwiegende Mehrzahl der Leukozytenbestimmungen im Harn werden in der medizinischen Praxis nach der sogenannten Gesichtsfeldmethode im Harnsediment durchgeführt. Hierzu muss zunächst das Untersuchungsgut (Sediment) durch Zentrifugieren gewonnen werden. Dabei werden jedoch auch andere Bestandteile des Harnes angereichert, die - wie z.B. Salze und Epithelzellen - die mikroskopische Auszählung der Leukozyten beträchtlich erschweren können. Schwankender Sedimentgehalt, Inhomogenitäten des Sedimentes, sowie womöglich unterschiedliche mikroskopische Vergrösserungen oder unterschiedliche optische Ausstattung der Mikroskope führen dazu, dass die hier übliche Angabe über die Anzahl der Leukozyten pro mikroskopischem Gesichtsfeld mit Fehlern von mehreren hundert Prozent behaftet sein kann.The vast majority of leukocyte determinations in urine are carried out in medical practice using the so-called visual field method in urine sediment. To do this, the test material (sediment) must first be obtained by centrifugation. However, other components of the urine are also enriched, such as Salts and epithelial cells - can make microscopic counting of leukocytes considerably more difficult. Fluctuating sediment content, inhomogeneity of the sediment, as well as possibly different microscopic magnifications or different optical equipment of the microscopes mean that the usual information about the number of leukocytes per microscopic field of view can be affected by errors of several hundred percent.

Aufgabe der vorliegenden Erfindung war es daher, ein diagnostisches Mittel bereitzustellen, mit dem die Leukozyten in Körperflüssigkeiten auf einfache und leicht zu handhabende Weise sowie möglichst schnell und vollständig nachgewiesen werden können.The object of the present invention was therefore to provide a diagnostic agent with which the leukocytes in body fluids can be detected in a simple and easy-to-use manner and as quickly and completely as possible.

Als Nachweisprinzip für einen solchen Leukozytentest bietet sich eine enzymatische Reaktion an, da die Leukozyten ein breitgefächertes Enzymspektrum besitzen.An enzymatic reaction lends itself to the principle of detection for such a leukocyte test, since the leukocytes have a broad spectrum of enzymes.

In dem US-Patent 30 87 794 ist bereits ein Leukozytennachweis beschrieben und beansprucht, der über die in den granulozytären Leukozyten vorhandene peroxidatische Aktivität geführt wird. Ein saugfähiger Träger, der mit Wasserstoffperoxid und einem organischen Indikator, beispielsweise o-Tolidin, imprägniert ist, zeigt die Anwesenheit von Leukozyten durch die Bildung eines farbigen Oxidationsproduktes an. Ein solcher Test besitzt jedoch entscheidende Nachteile: Zum einen besitzen peroxidatische Reaktionen unter Verwendung von o-Tolidin ganz allgemein gegenüber reduzierenden Substanzen im Harn, wie z.B. gegenüber Ascorbinsäure, eine erhebliche Störanfälligkeit. Darüber hinaus finden sich in mehreren Literaturstellen (s. z.B. L. Mettler, Med. Welt 23, 399 [1972]) Hinweise auf die Instabilität der Leukozytenperoxidase im Harnmilieu, die zu falschnegativen Befunden Anlass gibt. Noch gravierender ist die zu erwartende mangelhafte Selektivität dieses Testes gegenüber Erythrozyten.US Pat. No. 3,087,794 describes and claims a leukocyte detection which is carried out via the peroxidatic activity present in the granulocytic leukocytes. An absorbent carrier impregnated with hydrogen peroxide and an organic indicator, for example o-tolidine, indicates the presence of leukocytes by the formation of a colored oxidation product. However, such a test has decisive disadvantages: On the one hand, peroxidatic reactions using o-tolidine generally have a reducing effect on reducing substances in the urine, e.g. against ascorbic acid, a considerable susceptibility to interference. In addition, several references (see e.g. L. Mettler, Med. Welt 23, 399 [1972]) provide information on the instability of leukocyte peroxidase in the urinary environment, which gives rise to false negative results. The expected poor selectivity of this test towards erythrocytes is even more serious.

Seit einigen Jahren haben in der histo- und zytochemischen Enzymologie Nachweismethoden ihren festen Platz, die auf der esterolytischen Aktivität der in den zu bestimmenden Systemen vorhandener Enzyme beruhen (vgl. z.B. A.G.E. Pearse, Histochemistry, Theoretical and Applied). Im Prinzip werden dabei farblose oder schwach gefärbte Ester eingesetzt, die durch die enzymatische Spaltung zumeist in eine farblose Säure- und eine ebenfalls farblose Alkohol-(Phenol)-Komponente zerfallen. Letztere wird dann in einer der enzymatischen Verseifung folgenden Reaktion zu farbigen Produkten umgesetzt (z.B. Kupplung mit Diazoniumsalzen oder oxidative Reaktionen).For several years, detection methods based on the esterolytic activity of the enzymes present in the systems to be determined have had a permanent place in histochemical and cytochemical enzymology (see e.g. A.G.E. Pearse, Histochemistry, Theoretical and Applied). In principle, colorless or weakly colored esters are used, which mostly break down into a colorless acid and also a colorless alcohol (phenol) component due to the enzymatic cleavage. The latter is then converted to colored products in a reaction following enzymatic saponification (e.g. coupling with diazonium salts or oxidative reactions).

So beschreiben beispielsweise F. Schmalzl und H. Braunsteiner in Klin. Wschr. 46, 642 (1968) einen spezifischen zytochemischen Leukozytenesterase-Nachweis mit Naphthol-AS-D-chloracetat als Substrat und einem Diazoniumsalz zur Bildung der farbigen Azo-Verbindung.For example, F. Schmalzl and H. Braunsteiner in Klin. Wschr. 46, 642 (1968) a specific cytochemical detection of leukocyte esterase with naphthol-AS-D-chloroacetate as substrate and a diazonium salt to form the colored azo compound.

Für ein diagnostisches Mittel zum schnellen und einfachen Nachweis von Leukozyten in Körperflüssigkeiten, wie z.B. im Harn, erweisen sich Zwei-Komponenten-Systeme dieser Art als nicht geeignet, da bekanntlich viele im Harn vorkommende Verbindungen, wie Urobilinogen, Stercobilinogen, Bilirubin u.a., mit Diazoniumsalzen reagieren. Darüber hinaus ist dieser Nachweis viel zu unempfindlich. Beispielsweise zeigen Proben mit 5000 Leukozyten/Ill keine Reaktion.Two-component systems of this type have not proven to be suitable for a diagnostic means for the quick and simple detection of leukocytes in body fluids, such as in urine, since it is known that many compounds found in urine, such as urobilinogen, stercobilinogen, bilirubin and others, with diazonium salts react. In addition, this proof is far too insensitive. For example, samples of 5000 leukocytes / I ll no reaction.

In dem britischen Patent 11 28 371 wird nun ein diagnostisches Mittel zum Nachweis hydrolytischer Enzyme in Körperflüssigkeiten beschrieben und beansprucht. Hierbei wird ein saugfähiger Träger mit farblosen Indoxyl- oder Thioindoxyl-Estern und gegebenenfalls einem Puffer und einem Oxidationsmittel getränkt. Bei Anwesenheit hydrolytischer Enzyme entstehen aus den Estern freies Indoxyl oder Thioindoxyl und hieraus durch Einwirkung von Luftsauerstoff oder Oxidationsmittel tiefgefärbtes Indigo oder Thioindigo. Die in diesem Patent beanspruchten Verbindungen sind für einen Leukozytentest nicht brauchbar, da sie selbst mit 10 000 Leukozyten/µI keine Reaktion zeigen.British patent 11 28 371 describes and claims a diagnostic agent for the detection of hydrolytic enzymes in body fluids. Here, an absorbent carrier is impregnated with colorless indoxyl or thioindoxyl esters and optionally a buffer and an oxidizing agent. In the presence of hydrolytic enzymes, free indoxyl or thioindoxyl is formed from the esters and from this deeply colored indigo or thioindigo by the action of atmospheric oxygen or oxidizing agent. The compounds claimed in this patent are not useful for a leukocyte test because they show no reaction even at 10,000 leukocytes / µI.

So ist bis heute kein Teststreifen im Handel, der es gestattet, einfach und schnell Leukozyten nachzuweisen, obwohl der Leukozytennachweis im Harn zu der am häufigsten durchgeführten klinischen Untersuchung gehört.To date, there is no test strip on the market that it allows easy and quick detection of leukocytes, although the detection of leukocytes in the urine is one of the most frequently performed clinical tests.

Überraschenderweise wurde nun gefunden, dass man stabile und schnell anzeigende diagnostische Mittel, mit denen Leukozyten gut in Körperflüssigkeiten nachzuweisen sind, erhält, wenn als Substrate zum Nachweis der in den neutrophilen Leukozyten-Granulozyten vorkommenden Esterasen (Proteasen), Indoxyl- oder Thioindoxyl-Aminosäureester oder -Peptidester verwendet werden. Darüber hinaus zeigte sich, dass sich diese Substrate auch ausgezeichnet zum allgemeinen Nachweis proteolytischer Enzyme, wie z.B. von Elastase, Chymotrypsin oder Trypsin in rein wässrigen Lösungen oder auch in Körperflüssigkeiten, wie z.B. Plasma, Serum, Liquor, Pankreassekret oder wässrigen Stuhlextrakten, eignen.Surprisingly, it has now been found that stable and rapidly indicating diagnostic agents with which leukocytes can be readily detected in body fluids are obtained when substrates for the detection of the esterases (proteases), indoxyl or thioindoxyl amino acid esters or present in the neutrophilic leukocyte granulocytes -Peptide esters can be used. In addition, it was shown that these substrates are also excellent for the general detection of proteolytic enzymes, e.g. of elastase, chymotrypsin or trypsin in purely aqueous solutions or also in body fluids, e.g. Plasma, serum, cerebrospinal fluid, pancreatic secretions or aqueous stool extracts are suitable.

Gegenstand der vorliegenden Erfindung ist daher ein diagnostisches Mittel zum Nachweis proteolytischer Enzyme, insbesondere zum Nachweis der in den Leukozyten vorhandenen Proteasen in Körperflüssigkeiten, bestehend aus einem saugfähigen Träger, einer Filmschicht, einer Pulvermischung, einem Lyophilisat, einer Lösung oder einer Reagenztablette, enthaltend ein oder mehrere Chromogene und jeweils übliche Zusatzstoffe, dadurch gekennzeichnet, dass als Chromogene Indoxyl- und/oder Thioindoxyl-Aminosäureester und/oder -Peptidester der allgemeinen Formel I

Figure imgb0001
in der

  • Ri, R2, R3, R4, die gleich oder verschieden sein können, jeweils Wasserstoff oder Halogen, eine niedere Alkyl-, niedere Alkoxy-, Aryl-, Aralkyl-, Aralkoxy-, eine Hydroxy-, eine Carboxy-, eine Carboxy-nieder-Alkoxy-, eine Aralkoxycarbonyl-, eine Aralkoxycarbonyl-nieder-Alkoxy-, eine Nitro-oder eine niedere Acylaminogruppe oder jeweils zwei benachbarte Substituenten einen gegebenenfalls durch Halogen substituierten benzoannellierten Rest,
  • X ein Schwefelatom oder eine gegebenenfalls durch einen niederen Alkyl-, einen Aryl-, einen Aralkyl-oder einen Acylrest substituierte Iminogruppe,
  • A einen Aminosäure- oder einen Peptidrest, B eine in der Peptidchemie übliche oder davon abgeleitete Stickstoffschutzgruppe bedeutet, eingesetzt werden.
The present invention therefore relates to a diagnostic agent for the detection of proteolytic enzymes, in particular for the detection of the proteases present in the leukocytes in body fluids, consisting of an absorbent carrier, a film layer, a powder mixture, a lyophilisate, a solution or a reagent tablet, containing one or several chromogens and conventional additives, characterized in that as chromogens indoxyl and / or thioindoxyl amino acid esters and / or peptide esters of the general formula I
Figure imgb0001
in the
  • R i , R 2 , R 3 , R 4 , which can be the same or different, each hydrogen or halogen, a lower alkyl, lower alkoxy, aryl, aralkyl, aralkoxy, a hydroxy, a carboxy, a carboxy-lower alkoxy, an aralkoxycarbonyl, an aralkoxycarbonyl-lower alkoxy, a nitro or a lower acylamino group or two adjacent substituents each an optionally halogen-substituted benzo-fused radical,
  • X is a sulfur atom or an imino group which is optionally substituted by a lower alkyl, an aryl, an aralkyl or an acyl radical,
  • A is an amino acid or a peptide residue, B is a nitrogen protecting group which is customary in peptide chemistry or is derived therefrom.

Ein weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung von Indoxyl- und/ oder Thioindoxyl-Aminosäureestern und/oder -Peptidestern der allgemeinen Formel zur Herstellung von diagnostischen Mitteln zum Nachweis proteolytischer Enzyme, insbesondere der in den Leukozyten vorhandenen Proteasen in Körperflüssigkeiten.Another object of the present invention is the use of indoxyl and / or thioindoxyl amino acid esters and / or peptide esters of the general formula for the preparation of diagnostic agents for the detection of proteolytic enzymes, in particular the proteases present in the leukocytes in body fluids.

Sämtliche Indoxyl- und Thioindoxyl-Aminosäureester und -Peptidester der allgemeinen Formel sind neue Verbindungen.All indoxyl and thioindoxyl amino acid esters and peptide esters of the general formula are new compounds.

Gegenstand der vorliegenden Erfindung sind daher ferner die Indoxyl- und Thioindoxyl-Aminosäureester und -Peptidester der allgemeinen Formel I sowie Verfahren zu deren Herstellung.The present invention therefore also relates to the indoxyl and thioindoxyl amino acid esters and peptide esters of the general formula I and processes for their preparation.

Die Herstellung der neuen Indoxyl- und Thioindoxyl-Aminosäureester und -Peptidester der allgemeinen Formel I kann nach an sich aus der Peptidchemie her bekannten Methoden erfolgen.The new indoxyl and thioindoxyl amino acid esters and peptide esters of the general formula I can be prepared by methods known per se from peptide chemistry.

Vorzugsweise werden in an sich bekannterweise die entsprechenden Indoxyl- oder Thioindoxyl-Verbindungen der allgemeinen Formel II

Figure imgb0002
in der Ri, R2, R3, R4 und X die oben angegebene Bedeutung haben, mit Aminosäuren und Peptiden der allgemeinen Formel III
Figure imgb0003
in der A und B die oben angegebene Bedeutung haben, beziehungsweise mit geeigneten reaktiven Derivaten davon, umgesetzt.Preferably, the corresponding indoxyl or thioindoxyl compounds of the general formula II are known
Figure imgb0002
in which R i , R 2 , R 3 , R 4 and X have the meaning given above, with amino acids and peptides of the general formula III
Figure imgb0003
in which A and B have the meaning given above, or with suitable reactive derivatives thereof.

Als reaktive Derivate werden z.B. die Säurechloride, beziehungsweise die bei der Peptidsynthese üblicherweise verwendeten Mischanhydride, beispielsweise mit Chlorameisensäureethylester oder Aktiv-Ester eingesetzt.As reactive derivatives e.g. the acid chlorides, or the mixed anhydrides usually used in peptide synthesis, for example with ethyl chloroformate or active ester.

Die Indoxyl- und Thioindoxyl-Verbindungen der allgemeinen Formel II, sowie die Aminosäuren und Peptide der allgemeinen Formel III sind bekannte Substanzen (vgl. beispielsweise P. Friedländer, Fortschritte der Teerfarbenfabrikation und verwandter Industriezweige, Bd. 3-20 bzw. Houben-Weyl, Methoden der organischen Chemie, Bd. 15/1), oder können in Analogie zu bekannten Verbindungen hergestellt werden.The indoxyl and thioindoxyl compounds of the general formula II, as well as the amino acids and peptides of the general formula III are known substances (see, for example, P. Friedländer, Advances in Tar Dye Manufacturing and Related Industries, Vol. 3-20 and Houben-Weyl, Methods of organic chemistry, Vol. 15/1), or can be prepared in analogy to known compounds.

Unter Halogen in der Definition von R1, R2, R3 und R4 ist Fluor, Chlor, Brom und lod, vorzugsweise Chlor und Brom zu verstehen.Halogen in the definition of R 1, R 2 , R 3 and R 4 is to be understood as fluorine, chlorine, bromine and iodine, preferably chlorine and bromine.

Die «niedere Alkoxygruppe» in der Definition von R1, R2, R3 und R4, sowie die «niedere Alkylgruppe» von R1, R2, R3, R4 und X enthalten 1 bis 5, vorzugsweise 1 bis 3 Kohlenstoffatome, wobei die Methoxy- und die Methylgruppe ganz besonders bevorzugt sind.The “lower alkoxy group” in the definition of R 1 , R 2 , R 3 and R 4 , and the “lower alkyl group” of R 1 , R 2 , R 3 , R 4 and X contain 1 to 5, preferably 1 to 3 Carbon atoms, with the methoxy and the methyl group being particularly preferred.

Unter einer «Aralkoxygruppe» in der Definition von Ri, R2, R3 und R4, sowie einer «Aralkylgruppe» in der Definition von R1, R2, R3, R4 und X sind z.B. durch Oxy-nieder-Alkyl- bzw. niedere Alkylreste substituierte Phenyl- und Naphthylgruppen zu verstehen, wobei der Alkylrest 1 bis 5, vorzugsweise 1 bis 3 Kohlenstoffatome enthält. Besonders bevorzugt sind der Benzyloxy- und der Benzylrest.An “aralkoxy group” in the definition of R i , R 2 , R 3 and R 4 , and an “aralkyl group” in the definition of R 1 , R 2 , R 3 , R 4 and X are, for example, by oxy-lower To understand alkyl or lower alkyl radicals substituted phenyl and naphthyl groups, the alkyl radical containing 1 to 5, preferably 1 to 3, carbon atoms. The benzyloxy and the benzyl radical are particularly preferred.

Als «niedere Acylaminogruppe» von Ri, R2, R3 und R4 kommen die Amidgruppierungen der niederen aliphatischen Carbonsäuren mit 1 bis 5, vorzugsweise 1 bis 3 Kohlenstoffatomen, in Frage. Besonders bevorzugt ist der Acetylaminorest. Als «Acylrest» in der Definition von X kommen die Reste aliphatischer Carbonsäuren mit 1 bis 5, vorzugsweise 1 bis 3 Kohlenstoffatomen, oder auch aromatischer Carbonsäuren, wie beispielsweise der Benzoe- oder Naphthoesäuren, in Frage. Besonders bevorzugt sind Acetyl- und Benzoylreste.The “lower acylamino group” of R i , R 2 , R 3 and R 4 are the amide groups of the lower aliphatic carboxylic acids having 1 to 5, preferably 1 to 3, carbon atoms. The acetylamino radical is particularly preferred. The “acyl radical” in the definition of X is the radicals of aliphatic carboxylic acids with 1 to 5, preferably 1 to 3, carbon atoms, or also aromatic carboxylic acids, such as, for example, benzoic or naphthoic acids. Acetyl and benzoyl radicals are particularly preferred.

Unter einem «Arylrest» in der Definition von R1, R2, R3, R4 und X sind vorzugsweise die Phenyl-oder die Naphthylgruppe zu verstehen.An “aryl radical” in the definition of R 1 , R 2 , R 3 , R 4 and X is preferably to be understood as the phenyl or naphthyl group.

Als «Aminosäurerest» in der Definition von A kommen vorzugsweise die Reste der natürlichen a-Aminosäuren in ihrer L- oder D-Form oder auch in ihrer racemischen Form, in Frage. Besonders bevorzugt sind die Reste von Glycin, Alanin, Valin, Leucin, Isoleucin, Phenylalanin und Tyrosin. Gegebenenfalls vorhandene freie Hydroxygruppen können acyliert, vorzugsweise acetyliert, sein.The “amino acid residue” in the definition of A is preferably the residues of the natural a-amino acids in their L or D form or also in their racemic form. The residues of glycine, alanine, valine, leucine, isoleucine, phenylalanine and tyrosine are particularly preferred. Any free hydroxyl groups present can be acylated, preferably acetylated.

Unter einem «Peptidrest» in der Definition von A sind z.B. Di-, Tri-, Tetra- und Pentapeptide, vorzugsweise Di- und Tripeptide, zu verstehen, wobei als Aminosäure-Komponenten vorzugsweise die oben erwähnten Aminosäuren Verwendung finden.Under a "peptide residue" in the definition of A are e.g. To understand di-, tri-, tetra- and pentapeptides, preferably di- and tripeptides, the amino acid components mentioned preferably being used as the amino acid components.

Als «in der Peptidchemie übliche Stickstoffschutzgruppe» in der Definition von B sind z.B. Acyl-, Oxycarbonyl-, Thiocarbonyl-, Sulfonyl-, Sulfenyl-, Vinyl-, Cyclohexenyl-, Phosphoryl- oder Carbamoyl-Gruppen zu verstehen.As "nitrogen protecting group common in peptide chemistry" in the definition of B are e.g. To understand acyl, oxycarbonyl, thiocarbonyl, sulfonyl, sulfenyl, vinyl, cyclohexenyl, phosphoryl or carbamoyl groups.

Die erfindungsgemäss als Chromogene verwendeten Indoxyl- oder Thioindoxyl-Aminosäureester und -Peptidester der allgemeinen Formel werden in Konzentrationen von 10-4 bis 1 mol/ Liter, vorzugsweise 10-3 bis 10-' mol/Liter Imprägnierlösung, Beschichtungsmasse oder zu untersuchender Flüssigkeit eingesetzt.The indoxyl or thioindoxyl amino acid esters and peptide esters of the general formula used according to the invention as chromogens are used in concentrations of 10 to 4 to 1 mol / liter, preferably 10 to 3 to 10 mol / liter of impregnating solution, coating composition or liquid to be examined.

Ein weiterer Bestandteil des diagnostischen Mittels zum Nachweis proteolytischer Enzyme und insbesondere der Leukozyten-Proteasen ist ein geeignetes Puffersystem. Hierzu kommen z.B. Phosphat-, Borat-, Barbiturat-, Tris-(hydroxymethyl)-aminomethan-(=Tris-)-, 2-Amino-2-methyl- propandiol-1,3-(=Amediol)- oder Aminosäure-Puffer in Frage, wobei pH-Wert und Kapazität so gewählt werden müssen, dass sich in der Messlösung bzw. auf dem Teststreifen ein pH-Wert von 6-10, vorzugsweise von 7-9, einstellt.Another component of the diagnostic agent for the detection of proteolytic enzymes and in particular the leukocyte proteases is a suitable buffer system. In addition come e.g. Phosphate, borate, barbiturate, tris (hydroxymethyl) aminomethane - (= tris -) -, 2-amino-2-methyl-propanediol-1,3 - (= amediol) - or amino acid buffer in question, the pH and capacity must be selected so that a pH of 6-10, preferably 7-9, is established in the measurement solution or on the test strip.

Weiterhin kann man bei der Herstellung des erfindungsgemässen diagnostischen Mittels zum Nachweis proteolytischer Enzyme, insbesondere der Leukozyten-Proteasen in Körperflüssigkeiten zusätzlich Oxidationsmittel verwenden, um die bei der enzymatischen Reaktion primär entstandenen Indoxyl- bzw. Thioindoxyl-Verbindungen zu den gefärbten Indigo- bzw. Thioindigo-Substanzen umzusetzen. Diese Oxidationsmittel, wie z.B. Kalium-hexacyanoferrat-III, Kaliumbromat, Kaliumchromat, Phenazin-methosulfat oder Tetrazoliumsalze werden in Konzentrationen von 10-4 bis 1 mol/Liter, vorzugsweise 10- bis 10-' mol/Liter Imprägnierlösung, Beschichtungsmasse oder zu untersuchender Flüssigkeit eingesetzt.In addition, in the production of the diagnostic agent according to the invention for the detection of proteolytic enzymes, in particular the leukocyte proteases in body fluids, additional oxidizing agents can be used in order to convert the indoxyl or thioindoxyl compounds, which primarily result from the enzymatic reaction, to the colored indigo or thioindigo compounds. Implement substances. These oxidizing agents, such as, for example, potassium hexacyanoferrate III, potassium bromate, potassium chromate, phenazine methosulfate or tetrazolium salts, are used in concentrations of 10 to 4 to 1 mol / liter, preferably 10 to 10 mol / liter, of impregnating solution, coating composition or liquid to be examined used.

Ein weiterer Bestandteil eines diagnostischen Mittels für den Nachweis proteolytischer Enzyme, insbesondere der Leukozyten-Proteasen, kann ein Netzmittel sein, da hierdurch etwas verkürzte Reaktionszeiten und z.T. brillantere Farben erzielt werden. Vorzugsweise werden nichtionogene aber auch amphotere, kationen- oder anionenaktive Netzmittel in Konzentrationen von 0.05-2%, vorzugsweise 0.1-1 %, eingesetzt.A further component of a diagnostic agent for the detection of proteolytic enzymes, in particular leukocyte proteases, can be a wetting agent, since this results in somewhat shorter reaction times and sometimes. brilliant colors can be achieved. Nonionic but also amphoteric, cationic or anionic wetting agents are preferably used in concentrations of 0.05-2%, preferably 0.1-1%.

Zur Herstellung des erfindungsgemässen Mittels werden z.B. saugfähige Träger, vorzugsweise Filterpapier, Cellulose oder Kunstfaservliese, mit Lösungen der erforderlichen, üblicherweise zur Herstellung von Teststreifen verwendeten Reagenzien (Substrat, Puffer, gegebenenfalls Netzmittel, Oxidationsmittel etc.) in leichtflüchtigen Lösungsmitteln, wie z.B. Wasser, Methanol, Ethanol oder Aceton, imprägniert. Dies geschieht zweckmässig in zwei getrennten Schritten: Zunächst wird mit einer wässrigen Lösung imprägniert, die den Puffer und andere wasserlösliche Zusatzstoffe enthält. Danach wird mit einer Lösung der Protease-Substrate der allgemeinen Formel I imprägniert. In speziellen Fällen kann auch die umgekehrte Imprägnierfolge angewandt werden.For the preparation of the agent according to the invention e.g. absorbent carrier, preferably filter paper, cellulose or synthetic fiber fleece, with solutions of the necessary reagents (substrate, buffer, optionally wetting agent, oxidizing agent, etc.) usually used for the production of test strips in volatile solvents, such as e.g. Water, methanol, ethanol or acetone, impregnated. This is conveniently done in two separate steps: First, impregnation with an aqueous solution that contains the buffer and other water-soluble additives. It is then impregnated with a solution of the protease substrates of the general formula I. In special cases the reverse impregnation sequence can also be used.

Die fertigen Testpapiere können als solche verwendet werden oder in an sich bekannter Weise an Griffen angeklebt oder vorzugsweise zwischen Kunststoffen und feinmaschigen Netzwerken gemäss DBP 21 18 455 eingesiegelt werden.The finished test papers can be used as such or glued to handles in a manner known per se or preferably sealed between plastics and fine-meshed networks in accordance with DBP 21 18 455.

Zur Herstellung filmbeschichteter Teststreifen werden sämtliche Reagenzien in die Lösung oder Dispersion einer filmbildenden Substanz, wie z.B. Polyvinylester oder Polyamid, eingetragen und homogen vermischt. Das Gemisch wird in dünner Schicht auf einen Kunststoffträger gestrichen und getrocknet. Die erfindungsgemässen filmbeschichteten Teststreifen werden nach dem Trocknen geschnitten und können als solche verwendet werden oder in an sich bekannter Weise an Griffen angeklebt werden oder z.B. zwischen Kunststoffen und feinmaschigen Netzwerken gemäss DBP 21 18 455 eingesiegelt werden.To produce film-coated test strips, all reagents are dissolved in the solution or dispersion of a film-forming substance, e.g. Polyvinyl ester or polyamide, registered and mixed homogeneously. The mixture is spread in a thin layer on a plastic carrier and dried. The film-coated test strips according to the invention are cut after drying and can be used as such or glued to handles in a manner known per se or e.g. between plastics and fine-mesh networks according to DBP 21 18 455.

Das erfindungsgemässe diagnostische Mittel zum Nachweis proteolytischer Enzyme, insbesondere der Leukozyten-Proteasen, in Form von Pulvermischungen oder Reagenztabletten lässt sich herstellen, indem die oben angeführten Bestandteile des Testes mit üblichen galenischen Zusatzstoffen versetzt und granuliert werden. Zusatzstoffe dieser Art sind z.B. Kohlenhydrate, wie z.B. Mono-, Oligo- oder Polysaccharide, oder Zuckeralkohole, wie z.B. Mannit, Sorbit oder Xylit, oder andere lösliche inerte Verbindungen, wie Polyäthylenglykole oder Polyvinylpyrrolidon. Die Pulvermischungen oder Reagenztabletten weisen im allgemeinen ein Endgewicht von ungefähr 50-200 mg, vorzugsweise 50-80 mg, auf.The diagnostic agent according to the invention for the detection of proteolytic enzymes, in particular the leukocyte proteases, in the form of powder mixtures or reagent tablets can be produced by adding the usual components of the test to the components of the test and granulating them. Additives of this type are e.g. Carbohydrates, e.g. Mono-, oligo- or polysaccharides, or sugar alcohols, e.g. Mannitol, sorbitol or xylitol, or other soluble inert compounds such as polyethylene glycols or polyvinylpyrrolidone. The powder mixtures or reagent tablets generally have a final weight of approximately 50-200 mg, preferably 50-80 mg.

Zur Herstellung von Lyophilisaten im Gesamtgewicht von jeweils etwa 5-20 mg, vorzugsweise etwa 10 mg, wird eine Lösung gefriergetrocknet, die neben sämtlichen für den Test benötigten Reagenzien übliche Gerüstbildner, wie z.B. Polyvinylpyrrolidon, und evtl. weitere Füllstoffe, wie z.B. Mannit, Sorbit oder Xylit, enthält.For the production of lyophilisates with a total weight of about 5-20 mg, preferably about 10 mg, a solution is freeze-dried which, in addition to all the Re Agents customary scaffolders, such as polyvinyl pyrrolidone, and possibly other fillers, such as mannitol, sorbitol or xylitol, contains.

Das erfindungsgemässe diagnostische Mittel in Form einer Lösung enthält vorzugsweise sämtliche für den Test benötigten Reagenzien. Als Lösungsmittel kommen Wasser oder Gemische von Wasser mit einem wasserlöslichen organischen Lösungsmittel, wie z.B. Methanol, Ethanol, Aceton oder Dimethylformamid, in Frage. Aus Haltbarkeitsgründen kann es vorteilhaft sein, die für den Test .benötigten Reagenzien auf zwei oder mehr Lösungen zu verteilen, die erst bei der eigentlichen Untersuchung zusammengegeben werden.The diagnostic agent according to the invention in the form of a solution preferably contains all the reagents required for the test. Water or mixtures of water with a water-soluble organic solvent, such as e.g. Methanol, ethanol, acetone or dimethylformamide, in question. For reasons of durability, it can be advantageous to distribute the reagents required for the test over two or more solutions, which are only combined during the actual examination.

Die so hergestellten diagnostischen Mittel ermöglichen es, nach Eintauchen in die zu untersuchende oder nach Zugabe zur betreffenden Körperflüssigkeit die Anwesenheit proteolytischer Enzyme, insbesondere der Leukozyten-Proteasen, rasch und einfach über eine Farbbildung nachzuweisen, die visuell oder photometrisch, z.B. remissionsphotometrisch oder in der Küvette, beurteilt werden kann. Da die Aktivität der Leukozyten-Proteasen pro Zelle als eine im wesentlichen konstante Grösse angesehen werden kann, lässt sich aus der Intensität der Farbbildung die Leukozytenkonzentration der untersuchten Körperflüssigkeit ermitteln. Dabei werden mit dem erfindungsgemässen diagnostischen Mittel sowohl intakte als auch lysierte Leukozyten erfasst, da die Aktivität der Leukozyten-Proteasen auch nach der Lyse der Leukozyten voll erhalten bleibt. Ein Lysefehlertritt folglich nicht auf.The diagnostic agents thus prepared make it possible to quickly and easily detect the presence of proteolytic enzymes, in particular the leukocyte proteases, after immersion in the body fluid to be examined or after addition to the relevant body fluid, by color formation that can be visual or photometric, e.g. remission photometric or in the cuvette. Since the activity of the leukocyte proteases per cell can be regarded as an essentially constant variable, the leukocyte concentration of the examined body fluid can be determined from the intensity of the color formation. Both intact and lysed leukocytes are detected with the diagnostic agent according to the invention, since the activity of the leukocyte proteases is fully retained even after the leukocytes have been lysed. A lysis error therefore does not occur.

Beispiel 1example 1

Filterpapier (z.B. Schleicher + Schüll 23 SL) wird nacheinander mit den folgenden Lösungen imprägniert und dann bei 60 °C getrocknet.

Figure imgb0004
Figure imgb0005
Filter paper (eg Schleicher + Schüll 23 SL) is successively impregnated with the following solutions and then dried at 60 ° C.
Figure imgb0004
Figure imgb0005

Man erhält ein farbloses Testpapier, welches sich beim Eintauchen in leukozytenhaltige Harne je nach Leukozytenkonzentration helltürkis bis blau verfärbt. Es lassen sich nachweisen:

  • 5000 Leukozyten/Ill Harn in ca. 2 Minuten
  • 1000 Leukozyten/µl Harn in ca. 6 Minuten
  • 500 Leukozyten/µl Harn in ca. 10 Minuten
  • 200 Leukozyten/µl Harn in ca. 15 Minuten.
A colorless test paper is obtained which, when immersed in urine containing leukocytes, changes color from light turquoise to blue depending on the leukocyte concentration. The following can be demonstrated:
  • 5000 leukocytes / I ll urine in about 2 minutes
  • 1000 leukocytes / µl urine in about 6 minutes
  • 500 leukocytes / µl urine in about 10 minutes
  • 200 leukocytes / µl urine in approx. 15 minutes.

Die Empfindlichkeit des Testes liegt bei etwa 200 Leukozyten/µl. Die Beurteilung kann auch remissionsphotometrisch bei 620 nm vorgenommen werden.The sensitivity of the test is around 200 leukocytes / µl. The assessment can also be carried out using reflectance photometry at 620 nm.

Testpapiere mit ähnlichen Eigenschaften (Empfindlichkeiten: 200-2 000 Leukozyten/µl erhält man, wenn man anstelle von 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-indol die folgenden Substrate einsetzt, wobei sich - wenn nicht besonders erwähnt - ebenfalls helltürkise bis blaue Verfärbungen der sonst farblosen Testpapiere beim Eintauchen in leukozytenhaltige Harne beobachten lassen:

  • 1.1. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-4-methyl-indol
  • 1.2. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-5-methyl-indol
  • 1.3. 3-[N-(Benzyloxycarbonyl) -L-alanyloxy]-6-methyl-indol
  • 1.4. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-7-methyl-indol
  • 1.5. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-4,7-dimethyl-indol
  • 1.6. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-4-chlor-indol
  • 1.7. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-5-brom-indol
  • 1.8. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-6-chlor-indol Verfärbung: farblos nach purpur
  • 1.9. 3-[N-(Toluol- 4'-sulfonyl)-L-alanyloxy]-4-chlor-5-brom-indol
  • 1.10. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4,5,7-trichlor-indol
  • 1.11. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-chlor-5-brom-7-methyl-indol
  • 1.12. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-hydroxy-indol
  • 1.13. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-5-methoxy-indol
  • 1.14. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-benzyloxy-indol .
  • 1.15. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-carboxy-indol
  • 1.16. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-benzyloxycarbonyl-indol
  • 1.17. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-(carboxy-methoxy)-indol
  • 1.18. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxyl-5-(benzyloxycarbonyl-methoxy)-indol
  • 1.19. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxyl-6-nitro-indol
  • 1.20. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-6-acetylamino-indol
  • 1.21. 3-[N-(Toluot-4'-sulfonyl)-L-alanyloxy]-benzo[g]-indol Verfärbung: farblos nach grün.
  • 1.22. 1-Methyl-3-[N-(benzyloxycarbonyl)-L-alanyloxy]-indol Verfärbung: farblos nach grün.
  • 1.23 1-Benzyl-3-[N-(toluol-4'-sulfonyl)- L-alanyloxy]-indol Verfärbung: farblos nach grün.
  • 1.24. 1-Phenyl-3-[N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol Verfärbung: farblos nach blaugrün.
  • 1.25 1-Acetyl-3-[N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol Verfärbung: farblos nach rot.
  • 1.26. 1-Benzoyl-3-(N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol Verfärbung: farblos nach violett.
  • 1.27. 3-[N-(Benzyloxycarbonyl)-glycyloxy]-indol
  • 1.28. 3-[N-(Toluol-4'-sulfonyl)-glycyloxy]-indol
  • 1.29. 3-[N-(Toluol-2'-sulfonyl)-L-alanyloxy]-indol
  • 1.30. 3-[N-(Toluol-3'-sulfonyl)-L-alanyloxy]-indol
  • 1.31. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-indol
  • 1.32. 3-[N-(Toluoi-4'-sulfonyl)-D-alanyloxy]-indol
  • 1.33. 3-[N-(Benzyloxycarbonyl)-D,L-alanyloxy]-indol
  • 1.34. 3-[N-Benzyloxycarbonyl)-L-valyloxy]-indol
  • 1.35. 3-[N-(Toluol-4'-sulfonyl)-L-valyloxy]-indol
  • 1.36. 3-[N-(Benzyloxycarbonyl)-L-leucyloxy]-indol
  • 1.37. 3-[N-(Benzyloxycarbonyl)-L-isoleucyloxy]-indol
  • 1.38. 3-[N-(Benzyloxycarbonyl)-L-phenylalanyloxy]-indol
  • 1.39. 3-(N-(Toluol-4'-sulfonyl)-L-phenylalanyloxy]-indol
  • 1.40. 3-[N-Acetyl-L-tyrosyloxy]-indol
  • 1.41. 3-[N-Benzoyl-L-tyrosyloxy]-indol
  • 1.42. 3-[N-(Benzyloxycarbonyl)-L-tyrosyloxy]-indol
  • 1.43. 3-[N-(Toluol-4'-sulfonyl)-L-tyrosyloxy]-indol
  • 1.44. 3-[N-(Toluol-4'-sulfonyl)-0-acetyl-L-tyrosyloxy]-indol
  • 1.45. 3-[N-(Benzyloxycarbonyl)-L-alanyl-L-alanyloxy]-indol
  • 1.46. 3-[N-(Toluol-4'-sulfonyl)-D-alanyl-L-alanyloxy]-indol
  • 1.47. 3-[N-(Benzyloxycarbonyl)-L-alanyl-L-alanyl-L-alanyloxy]-indol
  • 1.48. 3-[N-(Toluol-4'-sulfonyl)-D-alanyl-D-alanyl-L-alanyloxy]-indol
  • 1.49. 3-[N-Formyl-L-alanyloxy]-indol
  • 1.50. 3-[N-Acetyl-L-alanyloxy]-indol
  • 1.51. 3-[N-Succinyl-L-alanyloxy]-indol
  • 1.52. 3-[N-Benzoyl-D,L-alanyloxy]-indol
  • 1.53. 3-[N-Phthaloyl-L-alanyloxy]-indol
  • 1.54. 3-[N-(Ethoxycarbonyl)-L-alanyloxy]-indol
  • 1.55. 3-[N-(tert.-Butyloxycarbonyl)-L-alanyloxy]-indol
  • 1.56. 3-[N-(3',6'-Dioxa-n-heptyloxycarbonyl)-L-alanyloxy]-indol
  • 1.57. 3-[N-(Cyclohexyloxycarbonyl)-L-alanyloxy]-indol
  • 1.58. 3-[N-(Phenyloxycarbonyl)-L-alanyloxy]-indol
  • 1.59. 3-[N-(4'-Methyl-benzyloxycarbonyl)-L-alanyloxy]-indol
  • 1.60. 3-[N-(4'-Methoxy-benzyloxycarbonyl)-L-alanyloxy]-indol
  • 1.61. 3-[N-(4'-Nitro-benzyloxycarbonyl)-L-alanyloxy]-indol
  • 1.62. 3-[N-(N'-(Piperidino)-oxycarbonyl)-L-alanyloxy]-indol
  • 1.63. 3-[N-(Furyl-(2')-methoxycarbonyl)-L-alanyloxy]-indol
  • 1.64. 3-[N-(Thienyl-(2')-methoxycarbonyl)-L-alanyloxy]-indol
  • 1.65. 3-[N-(Benzylthiocarbonyl)-L-alanyloxy]-indol
  • 1.66. 3-[N-(Methansulfonyl)-L-alanyloxy]-indol
  • 1.67. 3-[N-(Benzylsulfonyl)-L-alanyloxy]-indol
  • 1.68. 3-[N-(Benzolsulfonyl)-L-alanyloxy]-indol
  • 1.69. 3-[N-(4'-Brom-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.70. 3-[N-(4'-Nitro-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.71. 3-[N-(4'-Dimethylamino-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.72. 3-[N-(4'-Acetylamino-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.73. 3-[N-(4'-n-Butyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.74. 3-[N-(4'-tert.-Butyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.75. 3-[N-(4'-n-Octyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.76. 3-[N-(4'-Hydroxy-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.77. 3-[N-(4'-Methoxy-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.78. 3-[N-(4'-Benzyloxy-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.79. 3-[N-(4'-(2"-Hydroxy-ethoxy)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.80. 3-[N-(4'-(3"-Oxa-5"-hydroxy-n-pentyl- oxy)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.81. 3-[N-(4'-(3",6"-Di-oxa-n-heptyloxy)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.82. 3-[N-( 4'-(2"-Hydroxy-ethyl)-benzol- sulfonyl)-L-alanyloxy]-indol
  • 1.83. 3-[N-(4'-(2"-{4"'-Nitro-benzyloxy}- ethyl)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.84. 3-[N-(4'-(2"-Chlor-ethyl)-benzolsulfo- nyl)-L-alanyloxy]-indol
  • 1.85. 3-[N-(4'-Acetyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.86. 3-[N-(4'-Cyano-benzolsulfonyl)-L-. alanyloxy]-indol
  • 1.87. 3-[N-(4'-Carboxy-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.88. 3-[N-(4'-Methoxycarbonyl-benzolsulfo- nyl)-L-alanyloxy]-indol
  • 1.89. 3-[N-(4'-Benzyloxycarbonyl-benzolsulfo- nyl)-L-alanyloxy]-indol
  • 1.90. 3-[N-(4'-Carbamoyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.91. 3-[N-(4'-(Dimethyl-carbamoyl)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.92. 3-[N-(4'-Carboxymethyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.93. 3-[N-(4'-Carboxymethoxy-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.94. 3-[N-(4'-Carboxymethylamino-benzolsul- fonyl)-L-alanyloxy]-indol
  • 1.95. 3-[N-(4'-(Benzyloxycarbonyl-methyl- amino)-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.96. 3-[N-(4'-FIuor-benzolsufonyl)-L-alanyloxy]-indol
  • 1.97. 3-[N-(4'-Fluorsulfonyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.98. 3-[N-(4'-Sulfamoyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.99. 3-[N-Methyl-N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol
  • 1.100. 3-[N-Acetyl-N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol
  • 1.101. 3-[N-(2',4',6'-Trimethyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 1.102. 3-[N-(Biphenyl-4'-sulfonyl)-L-alanyloxy]-indol
  • 1.103. 3-[N-(Naphthalin-2'-sulfonyl)-L-alanyloxyl-indol
  • 1.104. 3-[N-(4'-Acetylamino-naphthalin-1'-sulfonyl)-L-alanyloxy]-indol
  • 1.105. 3-[N-(5'-Dimethylamino-naphthalin- l'-sulfonyl)-L-alanyloxyl-Indol
  • 1.106. 3-[N-(Chinolin-8'-sulfonyl)-L-alanyloxy]-indol
  • 1.107. 3-[N-(F>yridin-3'-sulfonyl)-L-alanyloxy]-indol
  • 1.108. 3-[N-(2'-Nitro-benzolsulfonyl)-L-alanyloxy]-indol Verfärbung: gelb nach grün.
  • 1.109. 3-[N-(1'-Methyl-2'-benzoyl-vinyl)-L-alanyloxy]-indol
  • 1.110. 3-[N-(5',5'-Dimethyl-3'-oxo-cyclohexen-1'-yl)-L-alanyloxy]-indol
  • 1.111. 3-[N(Diphenylcarbamoyl)-L-alanyloxy]-indol
  • 1.112. 3-[N-(Di-(4'-nitrobenzyl)-phosphoryl)-L-alanyloxy]-indol
  • 1.113. 3-[N-(Di-(4'-brombenzyl)-phosphoryl)-L-alanyloxy]-indol
  • 1.114. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-benzyl-i ndol
  • 1.115. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-phenyl-indol
  • 1.116. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-methoxy-indol
Test papers with similar properties (sensitivities: 200-2,000 leukocytes / µl are obtained if, instead of 3- [N- (benzyloxycarbonyl) -L-alanyloxy] indole, the following substrates are used, although - if not specifically mentioned - also Have light turquoise to blue discoloration of the otherwise colorless test papers observed when immersed in leukocyte-containing urine:
  • 1.1. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -4-methyl-indole
  • 1.2. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -5-methyl-indole
  • 1.3. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -6-methyl-indole
  • 1.4. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -7-methyl-indole
  • 1.5. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -4,7-dimethyl-indole
  • 1.6. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -4-chloroindole
  • 1.7. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -5-bromo-indole
  • 1.8. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -6-chloro-indole Discoloration: colorless to purple
  • 1.9. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-chloro-5-bromo-indole
  • 1.10. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4,5,7-trichloroindole
  • 1.11. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-chloro-5-bromo-7-methyl-indole
  • 1.12. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-hydroxy-indole
  • 1.13. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -5-methoxy-indole
  • 1.14. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-benzyloxy-indole.
  • 1.15. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-carboxy-indole
  • 1.16. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-benzyloxycarbonyl-indole
  • 1.17. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5- (carboxymethoxy) indole
  • 1.18. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxyl-5- (benzyloxycarbonyl-methoxy) indole
  • 1.19. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxyl-6-nitro-indole
  • 1.20. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -6-acetylamino-indole
  • 1.21. 3- [N- (Toluot-4'-sulfonyl) -L-alanyloxy] -benzo [g] -indole Discoloration: colorless to green.
  • 1.22. 1-Methyl-3- [N- (benzyloxycarbonyl) -L-alanyloxy] indole Discoloration: colorless to green.
  • 1.23 1-Benzyl-3- [N- (toluene-4'-sulfonyl) - L-alanyloxy] indole Discoloration: colorless to green.
  • 1.24. 1-phenyl-3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] indole Discoloration: colorless to blue-green.
  • 1.25 1-Acetyl-3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] indole Discoloration: colorless to red.
  • 1.26. 1-Benzoyl-3- (N- (toluene-4'-sulfonyl) -L-alanyloxy] indole Discoloration: colorless to violet.
  • 1.27. 3- [N- (benzyloxycarbonyl) glycyloxy] indole
  • 1.28. 3- [N- (toluene-4'-sulfonyl) glycyloxy] indole
  • 1.29. 3- [N- (toluene-2'-sulfonyl) -L-alanyloxy] indole
  • 1.30. 3- [N- (toluene-3'-sulfonyl) -L-alanyloxy] indole
  • 1.31. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] indole
  • 1.32. 3- [N- (Toluoi-4'-sulfonyl) -D-alanyloxy] indole
  • 1.33. 3- [N- (Benzyloxycarbonyl) -D, L-alanyloxy] indole
  • 1.34. 3- [N-benzyloxycarbonyl) -L-valyloxy] indole
  • 1.35. 3- [N- (toluene-4'-sulfonyl) -L-valyloxy] indole
  • 1.36. 3- [N- (Benzyloxycarbonyl) -L-leucyloxy] indole
  • 1.37. 3- [N- (Benzyloxycarbonyl) -L-isoleucyloxy] indole
  • 1.38. 3- [N- (Benzyloxycarbonyl) -L-phenylalanyloxy] indole
  • 1.39. 3- (N- (toluene-4'-sulfonyl) -L-phenylalanyloxy] indole
  • 1.40. 3- [N-acetyl-L-tyrosyloxy] indole
  • 1.41. 3- [N-benzoyl-L-tyrosyloxy] indole
  • 1.42. 3- [N- (Benzyloxycarbonyl) -L-tyrosyloxy] indole
  • 1.43. 3- [N- (toluene-4'-sulfonyl) -L-tyrosyloxy] indole
  • 1.44. 3- [N- (toluene-4'-sulfonyl) -0-acetyl-L-tyrosyloxy] indole
  • 1.45. 3- [N- (Benzyloxycarbonyl) -L-alanyl-L-alanyloxy] indole
  • 1.46. 3- [N- (toluene-4'-sulfonyl) -D-alanyl-L-alanyloxy] indole
  • 1.47. 3- [N- (Benzyloxycarbonyl) -L-alanyl-L-alanyl-L-alanyloxy] indole
  • 1.48. 3- [N- (toluene-4'-sulfonyl) -D-alanyl-D-alanyl-L-alanyloxy] indole
  • 1.49. 3- [N-formyl-L-alanyloxy] indole
  • 1.50. 3- [N-acetyl-L-alanyloxy] indole
  • 1.51. 3- [N-succinyl-L-alanyloxy] indole
  • 1.52. 3- [N-benzoyl-D, L-alanyloxy] indole
  • 1.53. 3- [N-phthaloyl-L-alanyloxy] indole
  • 1.54. 3- [N- (Ethoxycarbonyl) -L-alanyloxy] indole
  • 1.55. 3- [N- (tert-Butyloxycarbonyl) -L-alanyloxy] indole
  • 1.56. 3- [N- (3 ', 6'-Dioxa-n-heptyloxycarbonyl) -L-alanyloxy] indole
  • 1.57. 3- [N- (Cyclohexyloxycarbonyl) -L-alanyloxy] indole
  • 1.58. 3- [N- (phenyloxycarbonyl) -L-alanyloxy] indole
  • 1.59. 3- [N- (4'-Methyl-benzyloxycarbonyl) -L-alanyloxy] indole
  • 1.60. 3- [N- (4'-Methoxy-benzyloxycarbonyl) -L-alanyloxy] indole
  • 1.61. 3- [N- (4'-Nitro-benzyloxycarbonyl) -L-alanyloxy] indole
  • 1.62. 3- [N- (N '- (Piperidino) oxycarbonyl) -L-alanyloxy] indole
  • 1.63. 3- [N- (Furyl- (2 ') methoxycarbonyl) -L-alanyloxy] indole
  • 1.64. 3- [N- (Thienyl- (2 ') methoxycarbonyl) -L-alanyloxy] indole
  • 1.65. 3- [N- (Benzylthiocarbonyl) -L-alanyloxy] indole
  • 1.66. 3- [N- (methanesulfonyl) -L-alanyloxy] indole
  • 1.67. 3- [N- (benzylsulfonyl) -L-alanyloxy] indole
  • 1.68. 3- [N- (benzenesulfonyl) -L-alanyloxy] indole
  • 1.69. 3- [N- (4'-Bromo-benzenesulfonyl) -L-alanyloxy] indole
  • 1.70. 3- [N- (4'-Nitro-benzenesulfonyl) -L-alanyloxy] indole
  • 1.71. 3- [N- (4'-Dimethylamino-benzenesulfonyl) -L-alanyloxy] indole
  • 1.72. 3- [N- (4'-Acetylamino-benzenesulfonyl) -L-alanyloxy] indole
  • 1.73. 3- [N- (4'-n-Butyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.74. 3- [N- (4'-tert-Butyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.75. 3- [N- (4'-n-Octyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.76. 3- [N- (4'-Hydroxy-benzenesulfonyl) -L-alanyloxy] indole
  • 1.77. 3- [N- (4'-Methoxy-benzenesulfonyl) -L-alanyloxy] indole
  • 1.78. 3- [N- (4'-Benzyloxy-benzenesulfonyl) -L-alanyloxy] indole
  • 1.79. 3- [N- (4 '- (2 "-hydroxy-ethoxy) -benzenesulfonyl) -L-alanyloxy] indole
  • 1.80. 3- [N- (4 '- (3 "-Oxa-5" -hydroxy-n-pentyl-oxy) -benzenesulfonyl) -L-alanyloxy] indole
  • 1.81. 3- [N- (4 '- (3 ", 6" -Di-oxa-n-heptyloxy) benzenesulfonyl) -L-alanyloxy] indole
  • 1.82. 3- [N- (4 '- (2 "-hydroxy-ethyl) -benzenesulfonyl) -L-alanyloxy] indole
  • 1.83. 3- [N- (4 '- (2 "- {4"' - Nitro-benzyloxy} ethyl) -benzenesulfonyl) -L-alanyloxy] indole
  • 1.84. 3- [N- (4 '- (2 "Chloro-ethyl) benzenesulfonyl) -L-alanyloxy] indole
  • 1.85. 3- [N- (4'-Acetyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.86. 3- [N- (4'-Cyano-benzenesulfonyl) -L-. alanyloxy] indole
  • 1.87. 3- [N- (4'-Carboxy-benzenesulfonyl) -L-alanyloxy] indole
  • 1.88. 3- [N- (4'-Methoxycarbonyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.89. 3- [N- (4'-Benzyloxycarbonyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.90. 3- [N- (4'-Carbamoyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.91. 3- [N- (4 '- (Dimethyl-carbamoyl) benzenesulfonyl) -L-alanyloxy] indole
  • 1.92. 3- [N- (4'-Carboxymethyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.93. 3- [N- (4'-Carboxymethoxy-benzenesulfonyl) -L-alanyloxy] indole
  • 1.94. 3- [N- (4'-Carboxymethylamino-benzenesulfonyl) -L-alanyloxy] indole
  • 1.95. 3- [N- (4 '- (Benzyloxycarbonyl-methylamino) -benzenesulfonyl) -L-alanyloxy] indole
  • 1.96. 3- [N- (4'-fluorobenzenesulfonyl) -L-alanyloxy] indole
  • 1.97. 3- [N- (4'-Fluorosulfonyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.98. 3- [N- (4'-Sulfamoyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1.99. 3- [N-Methyl-N- (toluene-4'-sulfonyl) -L-alanyloxy] indole
  • 1,100. 3- [N-acetyl-N- (toluene-4'-sulfonyl) -L-alanyloxy] indole
  • 1,101. 3- [N- (2 ', 4', 6'-trimethyl-benzenesulfonyl) -L-alanyloxy] indole
  • 1,102. 3- [N- (Biphenyl-4'-sulfonyl) -L-alanyloxy] indole
  • 1,103. 3- [N- (naphthalene-2'-sulfonyl) -L-alanyloxyl indole
  • 1,104. 3- [N- (4'-Acetylamino-naphthalene-1'-sulfonyl) -L-alanyloxy] indole
  • 1,105. 3- [N- (5'-Dimethylamino-naphthalene-l'-sulfonyl) -L-alanyloxyl indole
  • 1,106. 3- [N- (Quinoline-8'-sulfonyl) -L-alanyloxy] indole
  • 1.107. 3- [N- (F > yridin-3'-sulfonyl) -L-alanyloxy] indole
  • 1,108. 3- [N- (2'-Nitro-benzenesulfonyl) -L-alanyloxy] indole Discoloration: yellow to green.
  • 1,109. 3- [N- (1'-Methyl-2'-benzoyl-vinyl) -L-alanyloxy] indole
  • 1,110. 3- [N- (5 ', 5'-Dimethyl-3'-oxo-cyclohexen-1'-yl) -L-alanyloxy] indole
  • 1,111. 3- [N (Diphenylcarbamoyl) -L-alanyloxy] indole
  • 1,112. 3- [N- (Di- (4'-nitrobenzyl) phosphoryl) -L-alanyloxy] indole
  • 1,113. 3- [N- (Di- (4'-bromobenzyl) phosphoryl) -L-alanyloxy] indole
  • 1,114. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-benzyl-indole
  • 1,115. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-phenyl-indole
  • 1,116. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-methoxy-indole

Beispiel 2Example 2

Filterpapier (z.B. Schleicher + Schüll 23 SL) wird nacheinander mit den folgenden Lösungen imprägniert und dann bei 60 °C getrocknet.

Figure imgb0006
Figure imgb0007
Filter paper (eg Schleicher + Schüll 23 SL) is successively impregnated with the following solutions and then dried at 60 ° C.
Figure imgb0006
Figure imgb0007

Man erhält ein gelbgefärbtes Testpapier, welches sich beim Eintauchen in leukozytenhaltige Harne rot verfärbt.A yellow-colored test paper is obtained, which turns red when immersed in leukocyte-containing urine.

Die Empfindlichkeit des Testes liegt bei etwa 1000 Leukozyten/µl Harn.The sensitivity of the test is around 1000 leukocytes / µl urine.

Die Auswertung kann auch remissionsphotometrisch bei 576 nm durchgeführt werden.The evaluation can also be carried out at 576 nm using reflectance photometry.

Mit den Substraten des Beispiels 1 werden mit Oxidationsmitteln, wie beispielsweise dem oben verwendeten Kalium-hexacyano-ferrat-III, oder z.B. mit Kaliumbromat, Kaliumchromat, Phenazin-methosulfat oder Tetrazoliumsalzen, Testpapiere erhalten, die gegenüber analogen Testpapieren ohne Oxidationsmittel z.T. geringfügig verkürzte Reaktionszeiten aufweisen.The substrates of Example 1 are treated with oxidizing agents, such as, for example, the potassium hexacyano ferrate III used above, or e.g. with potassium bromate, potassium chromate, phenazine methosulfate or tetrazolium salts, test papers are obtained which, in part, compared to analog test papers without oxidizing agents. have slightly reduced response times.

Beispiel 3Example 3

Filterpapapier (z.B. Schleicher + Schüll 23 SL) wird nacheinander mit den folgenden Lösungen imprägniert und dann bei 60 °C getrocknet.

Figure imgb0008
Figure imgb0009
Filter paper (eg Schleicher + Schüll 23 SL) is successively impregnated with the following solutions and then dried at 60 ° C.
Figure imgb0008
Figure imgb0009

Man erhält ein farbloses Testpapier, welches sich beim Eintauchen in leukozytenhaltige Harne hell-türkis bis blau - je nach Leukozytenkonzentration - verfärbt. Gegenüber der Rezeptur des Beispiels 1 ergeben sich etwas verkürzte Reaktionszeiten und geringfügig brillantere Farben.A colorless test paper is obtained, which changes color from light turquoise to blue when immersed in leukocyte-containing urine, depending on the concentration of leukocytes. Compared to the recipe of Example 1, the reaction times are somewhat shorter and the colors are slightly more brilliant.

Auch mit den anderen Substraten der Beispiele 1 und 2 werden mit Netzmitteln, wie beispielsweise dem oben verwendeten Nonylphenolpolyglykolether (nichtionogen), aber auch z.B. mit Cocosimidazolin-Verbindungen (amphoter) oder Benzyltrimethylammoniumchlorid (kationenaktiv) oder Natriumsulfonato-dodecylbenzol (anionenaktiv), Testpapiere erhalten, die gegenüber analogen Testpapieren ohne Netzmittel z.T. geringfügig verkürzte Reaktionszeiten und etwas brillantere Farben aufweisen.Also with the other substrates of Examples 1 and 2, wetting agents such as the nonylphenol polyglycol ether (nonionic) used above, but also e.g. with cocosimidazoline compounds (amphoteric) or benzyltrimethylammonium chloride (cationic) or sodium sulfonato-dodecylbenzene (anionic), obtained test papers, some of which are comparable to analog test papers without wetting agents. have slightly reduced response times and somewhat more brilliant colors.

Beispiel 4Example 4

Figure imgb0010
Figure imgb0010
Figure imgb0011
Figure imgb0011
Figure imgb0012
Figure imgb0012

Es werden gemischt in einem Reagenzglas:

  • 1 ml Lösung 1
  • 1 ml Lösung 2
  • 2 ml leukozytenhaltiger Harn
The following are mixed in a test tube:
  • 1 ml solution 1
  • 1 ml solution 2
  • 2 ml of urine containing leukocytes

Das Gemisch verfärbt sich allmählich - je nach Leukozytenkonzentration - hellgrün bis tiefblau.The mixture gradually changes color - depending on the leukocyte concentration - from light green to deep blue.

Nach etwa 10 Minuten Stehenlassen bei Raumtemperatur wird die Leukozytenkonzentration visuell mit Hilfe von Vergleichsfarben bestimmt oder photometrisch, z.B. in 1 cm-Küvetten bei 620 nm.After standing for about 10 minutes at room temperature, the leukocyte concentration is determined visually using reference colors or photometrically, e.g. in 1 cm cuvettes at 620 nm.

Die Empfindlichkeit des Testes liegt bei etwa 200 Leukozyten/µl Harn.The sensitivity of the test is around 200 leukocytes / µl urine.

Auch mit den anderen Substraten der Beispiele 1 und 2 lassen sich Reagenzglas- bzw. Küvettenteste mit ähnlichen Empfindlichkeiten (200-1000 Leukozyten/µl Harn) durchführen.Test tube or cuvette tests with similar sensitivities (200-1000 leukocytes / µl urine) can also be carried out with the other substrates of Examples 1 and 2.

Beispiel 5Example 5

Figure imgb0013
wird zu 2 ml eines leukozytenhaltigen Harnes in einem Reagenzglas gegeben. Der Harn verfärbt sich allmählich - je nach Leukozytenkonzentration - hellgrün bis tiefblau.
Figure imgb0013
is added to 2 ml of urine containing leukocytes in a test tube. The urine gradually changes color - depending on the concentration of leukocytes - from light green to deep blue.

Nach 10 Minuten Stehenlassen bei Raumtemperatur wird die Leukozytenkonzentration visuell mit Hilfe von Vergleichsfarben bestimmt oder photometrisch, z.B. in 1 cm-Mikro-Küvetten bei 620 nm.After standing for 10 minutes at room temperature, the leukocyte concentration is determined visually with the aid of reference colors or photometrically, e.g. in 1 cm micro cuvettes at 620 nm.

Die Empfindlichkeit des Testes liegt bei etwa 200 Leukozyten/µl Harn. Die Reaktionszeit lässt sich deutlich verkürzen, wenn die Inkubation bei 37 °C durchgeführt wird.The sensitivity of the test is around 200 leukocytes / µl urine. The reaction time can be shortened significantly if the incubation is carried out at 37 ° C.

Mit den anderen Substraten der Beispiele 1 und 2 lassen sich ähnliche Empfindlichkeiten (200-1000 Leukozyten/µl) erreichen, wobei sich bei schwerlöslichen Substraten die Zugabe organischer Lösungsmittel, wie z.B. Methanol oder Dimethylformamid, empfiehlt.Similar sensitivities (200-1000 leukocytes / µl) can be achieved with the other substrates of Examples 1 and 2, with the addition of organic solvents, e.g. Methanol or dimethylformamide is recommended.

Beispiel 6Example 6

Filterpapier (z.B. Schleicher + Schüll 23 SL) wird nacheinander mit den folgenden Lösungen imprägniert und dann bei 60 °C getrocknet.

Figure imgb0014
Figure imgb0015
Filter paper (eg Schleicher + Schüll 23 SL) is successively impregnated with the following solutions and then dried at 60 ° C.
Figure imgb0014
Figure imgb0015

Man erhält ein farbloses Testpapier, welches sich beim Eintauchen in wässrige Lösungen, die das proteolytische Enzym Chymotrypsin enthalten, blau verfärbt. Es lassen sich so noch Konzentrationen von 0.02 U Chymotrypsin pro ml in ca. 6-7 Minuten nachweisen.A colorless test paper is obtained which turns blue when immersed in aqueous solutions which contain the proteolytic enzyme chymotrypsin. Concentrations of 0.02 U chymotrypsin per ml can be detected in about 6-7 minutes.

(Die angegebene Enzymaktivität wurde mit N-Acetyl-L-tyrosin-ethylester als Substrat bei 25 °C, pH 7,0 und λ = 237 nm bestimmt.)(The stated enzyme activity was determined with N-acetyl-L-tyrosine ethyl ester as substrate at 25 ° C., pH 7.0 and λ = 237 nm.)

Auch mit den anderen Substraten der Beispiele 1 und 2 lassen sich - je nach Aminosäure- bzw. Peptid rest - Chymotrypsin oder andere proteolytische Enzyme, wie z.B. Elastase oder Trypsin, in rein wässrigen Lösungen oder auch z.B. in Körperflüssigkeiten, wie z.B. Vollblut, Serum, Liquor, Pankreassekret oder wässrigen Stuhlextrakten, nachweisen.Depending on the amino acid or peptide residue, chymotrypsin or other proteolytic enzymes, such as e.g. Elastase or trypsin, in purely aqueous solutions or also e.g. in body fluids such as Detect whole blood, serum, cerebrospinal fluid, pancreatic secretions or watery stool extracts.

Beispiel 7Example 7 3-(N-(Toluol-4'-sulfonyl)-L-alanyloxy]-indol3- (N- (toluene-4'-sulfonyl) -L-alanyloxy] indole Lösung 1Solution 1

Zur Herstellung des Säurechlorids nach der Einstufen-Methode werden 5.35 g (0.022 mol) N-(Toluol-4-sulfonyl)-L-alanin in 20 ml abs. Dimethylformamid (DMF) gelöst und auf -30°C abgekühlt. Dann werden unter Rühren und Kühlen 1.76 ml (0.024 mol) Thionylchlorid zupipettiert und das Reaktionsgemisch 30 Minuten im Kältebad bei - 30 °C belassen.To prepare the acid chloride using the one-step method, 5.35 g (0.022 mol) of N- (toluene-4-sulfonyl) -L-alanine in 20 ml of abs. Dimethylformamide (DMF) dissolved and cooled to -30 ° C. Then 1.76 ml (0.024 mol) of thionyl chloride are pipetted in with stirring and cooling and the reaction mixture is left in the cold bath at -30 ° C. for 30 minutes.

Lösung 2Solution 2

In einen 250 ml-Dreihalskolben, der mit Rührer, Thermometer und einer Gas-Zu- und -Ableitung versehen ist, gibt man nach der vollständigen Entfernung der Luft durch einen schwachen Stickstoffstrom die Lösung von 2.90 g (0.022 mol) Indoxyl (3-Hydroxy-indol) in 40 ml abs. DMF, fügt 9.74 ml abs. Pyridin hinzu und kühlt auf -15°C ab.In a 250 ml three-necked flask equipped with a stirrer, thermometer and a gas inlet and outlet, the solution of 2.90 g (0.022 mol) of indoxyl (3-hydroxy) is added after the air has been completely removed by a gentle stream of nitrogen -indole) in 40 ml abs. DMF, adds 9.74 ml abs. Add pyridine and cool to -15 ° C.

Umsetzungimplementation

Man giesst Lösung 1 zu Lösung 2 und rührt unter Sauerstoff- und Wasserausschluss ca. 5 h bei -15 °C, bis mittels DC kein Indoxyl mehr zu erkennen ist.Solution 1 is poured into solution 2 and stirred with the exclusion of oxygen and water for about 5 h at -15 ° C. until no more indoxyl can be recognized by TLC.

Zur Aufarbeitung wird das Reaktionsgemisch im Vakuum bei maximal 40-50 °C Badtemperatur eingeengt. Der Rückstand wird in 100 ml Essigester aufgenommen und nacheinander zweimal mit je 30 ml 1 N Zitronensäure, 20 ml Wasser, 50 ml 5-proz. Natriumhydrogencarbonatlösung und 25 ml Wasser gewaschen. Die Essigesterphase wird - nach Trocknen mit Natriumsulfat - im Vakuum eingedampft.For working up, the reaction mixture is concentrated in vacuo at a maximum bath temperature of 40-50 ° C. The residue is taken up in 100 ml of ethyl acetate and successively twice with 30 ml of 1 N citric acid, 20 ml of water and 50 ml of 5 percent. Washed sodium bicarbonate solution and 25 ml of water. The ethyl acetate phase is - after drying with sodium sulfate - evaporated in vacuo.

Das so erhaltene Rohprodukt wird säulenchromatographisch an Kieselgel mit einem Toluol-Dioxan-Gemisch (9:1) gereinigt. Nach dem Abdestillieren des Lösungsmittels der gesammelten Fraktionen im Vakuum erhält man durch Anrühren des Rückstandes in Ether 1.45 g (18,4%) 3-[N-(Toluol-4'-sulfonyl)-L-alanlyolxy]-indol, farblose Kristalle, Schmp. 103 °C; α20 D: -56,6°, c = 1% (Methanol).The crude product thus obtained is purified by column chromatography on silica gel using a toluene / dioxane mixture (9: 1). After distilling off the solvent of the collected fractions in vacuo, the mixture is obtained by stirring Residue in ether 1.45 g (18.4%) 3- [N- (toluene-4'-sulfonyl) -L-alanlyolxy] indole, colorless crystals, mp. 103 ° C; α20 D: -56.6 °, c = 1% (methanol).

Als Nebenprodukt lässt sich aus anderen Fraktionen der o.a. säulenchromatographischen Trennung noch 0.89 g (11,3%) 1-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-3-hydroxy-indol = 1-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-3-oxo-indolin, aus Essigester: farblose Kristalle, Schmp. 187-188 °C,

Figure imgb0016
-41.7°, c = 1% (DMF), isolieren.As a by-product, 0.89 g (11.3%) of 1- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -3-hydroxy-indole = 1- [N- (Toluene-4'-sulfonyl) -L-alanyloxy] -3-oxo-indoline, from ethyl acetate: colorless crystals, mp. 187-188 ° C,
Figure imgb0016
Isolate -41.7 °, c = 1% (DMF).

In analoger Weise erhält man durch Umsetzung der entsprechend substituierten Indoxyl-Verbindungen mit den jeweiligen Aminosäuren die folgenden Substrate, wobei in allen Fällen (ausser 7.23. - 7.27.) als Nebenprodukte die o.a. 1-substituierten 3-Hydroxy-indole gebildet werden:

  • 7.1. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 123°C,
    Figure imgb0017
    (Methanol).
  • 7.2. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-4-methyl-indol, farblose Kristalle, Schmp. 113 °C,
    Figure imgb0018
    , c = 1% (Methanol).
  • 7.3. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-5-methyl-indol, farblose Kristalle, Schmp. 143-144 °C,
    Figure imgb0019
    , c = 1% (Methanol).
  • 7.4. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-6-methyl-indol, farblose Kristalle, Schmp. 148 °C,
    Figure imgb0020
    , c = 1 % Methanol).
  • 7.5. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-7-methyl-indol, farblose Kristalle, Schmp. 146 °C,
    Figure imgb0021
    , c = 1 % (Methanol).
  • 7.6. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-4,7-dimethyl-indol, farblose Kristalle, Schmp. 121 °C,
    Figure imgb0022
    , c = 1% (Methanol).
  • 7.7. 3-[N-Benzyloxycarbonyl)-L-alanyloxy]-4-chlor-indol, farblose Kristalle, Schmp. 142-143 °C,
    Figure imgb0023
    , c = 1% (Methanol).
  • 7.8. 3-[N-(Benzyloxycarbonyl)-L-alanyloxyl-5-brom-indol, farblose Kristalle, Schmp. 138 °C,
    Figure imgb0024
    , c = 1% (Methanol).
  • 7.9. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-6-chlor-indol, farblose Kristalle, Schmp. 170 °C,
    Figure imgb0025
    , c = 1% (Methanol).
  • 7.10. 3[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-chlor-5-brom-indol, farblose Kristalle, Schmp. 150-152 °C,
    Figure imgb0026
    , c = 1 % (Methanol).
  • 7.11. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4,5,7-trichlor-indol
  • 7.12. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-chlor-5-brom-7-methyl-indol schwach beigefarbene Kristalle, Schmp. 143-145 °C. DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 2:1, Detektion: UV, NH3 (Gas), RF-Wert: 0,56)
  • 7.13. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-hydroxy-indol
  • 7.14. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-5-methoxy-indol
  • 7.15. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-benzyloxy-indol
  • 7.16. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-carboxy-indol
  • 7.17. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-4-benzyloxycarbonyl-indol
  • 7.18. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-(carboxy-methoxy)-indol
  • 7.19. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-(benzyloxy-carbonyl- methoxy)-indol
  • 7.20. 3-[N-(Toluol-4'-sulfonyl )-L-alanyloxy]-6-nitro-indol
  • 7.21. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-6-acetylamino-indol
  • 7.22. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-benzo-[g]-indol
  • 7.23. 1-Methyl-3-[N-(benzyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 92 °C,
    Figure imgb0027
    , c = 1% (Methanol).
  • 7.24. 1-Benzyl-3-[N-toluol-4'-sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 149-152 °C,
    Figure imgb0028
    , c = 1% (DMF).
  • 7.25 1-Phenyl-3-[N-(toluol-4'-sulfonyl)-L-alanyloxyl]-indol
  • 7.26. 1-Acetyl-3-[N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol
  • 7.27. 1-Benzoyl-3-[N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 155-156 °C, α20 D: -54.7°, c = 1% (DMF).
  • 7.28. 3-[N-(Benzyloxycarbonyl)-glycyloxy]-indol, farblose Kristalle, Schmp. 122-124 °C.
  • 7.29. 3-[N-(Toluol-4'-sulfonyl)-glycyloxy]-indol, farblose Kristalle, Schmp. 103-105 °C.
  • 7.30. 3-[N-(Toluol-2'-sulfonyl)-L-alanyloxy]-indol farbloses amorphes Pulver; α20 D : -62.5°, c = 1 % (Methanol) DC: Fertigplatte Kieselgel (Laufmittel: Toluol-Dioxan 9:1
  • Detektion: UV, NH3 (Gas), RF-Wert: 0,20) 7.31. 3-[N-(Toluol-3'-sulfonyl)-L-alanyloxy]-indol farblose Kristalle, Schmp. 94°C; α20 D : - 54.9°, c = 1 % (Methanol)
  • 7.32. 3-[N-(Toluol-4'-sulfonyl)-D-alanyloxy]-indol, farblose Kristalle, Schmp. 98 °C, α20 D +53.1°, c = 1% (Methanol).
  • 7.33. 3-[N-(Benzyloxycarbonyl)-D,L-alanyloxy]-indol, farblose Kristalle, Schmp. 110-111 °C.
  • 7.34. 3-[N-(Benzyloxycarbonyl)-L-valyloxy]-indol, farblose Kristalle, Schmp. 64-65 °C, α20 D-41.1°, c = 1% (Methanol).
  • 7.35. 3-[N-(Benzyloxycarbonyl)-L-leucyloxyl-indol, farblose Kristalle, Schmp. 73-75 °C, α20D -42.2°, c = 1% (Methanol).
  • 7.36. 3-[N-(Benzyloxycarbonyl)-L-isoleucyloxy]-indol, farbloses, amorphes Pulver, α20 D -30.6°, c = 1 % (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 2:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.57).
  • 7.37. 3-[N-(Benzyloxycarbonyl)-L-phenylalanyloxy]-indol, gelbliche Kristalle, Schmp. 125 °C, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 9:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.56).
  • 7.38. 3-[N-(Toluol-4'-sulfonyl)-L-phenylalanyloxy]-indol, farblose Kristalle, Schmp. 167-169 °C, α20 D : -34.4°, c = 1% (Methanol).
  • 7.39. 3-[N-Acetyl-L-tyrosyloxy]-indol
  • 7.40. 3-[N-Benzoyl-L-tyrosyloxy]-indol
  • 7.41. 3-[N-(Benzyloxycarbonyl)-L-tyrosyloxy]-indol, farbloser, amorpher Schaum, α20 D: -22.6°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), Rr-Wert: 0.27).
  • 7.42. 3-[N-(Toluol-4'-sulfonyl)-L-tyrosyloxy]-indol, farblose Kristalle, Schmp. 171 °C, α20 D: -28.3°, c = 1% (Methanol).
  • 7.43. 3-[N-(Toluol-4'-sulfonyl)- O-acetyl-L-tyrosyloxy]-indol, farblose Kristalle, Schmp. 168-170 °C, α20 D : - 24.1°, c = 1 % (Dimethylformamid).
  • 7.44. 3-[N-(Benzyloxycarbonyl)-L-alanyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 144 °C, α20 D : -17.3°, c = 1% (Methanol).
  • 7.45. 3-[N-(Toluol-4'-sulfonyl)-D-alanyl-L-alanyloxy]-indol, gelblicher, amorpher Schaum, α20 D : +5.8°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.19).
  • 7.46. 3-[N-(Benzyloxycarbonyl)-L-alanyl-L-alanyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 156 °C, α20 D : -39.5°, c = 1% (Methanol).
  • 7.47. 3-[N-(Toluol-4'-sulfonyl)-D-alanyl-D-alanyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 216 °C, α20 D : +53.8°, c = 1 % (Methanol).
  • 7.48. 3-[N-Acetyl-L-alanyloxy]-indol, farbloser, amorpher Schaum, α20 D: -12.5°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Essigester-Dichlormethan 10:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.33).
  • 7.49. 3-[N-Succinyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 142 °C, α20 D : - 63.9°, c = 1 % (Methanol).
  • 7.50. 3-[N-Benzoyl-D,L-alanyloxy]-indol, farblose Kristalle, Schmp. 171 °C.
  • 7.51. 3-[N-Phthaloyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 58 °C, α20 D : -26.3°, c = 1% (Methanol).
  • 7.52. 3-[N-(Ethoxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 96 °C, α20 D : -68.9°, c = 1% (Methanol).
  • 7.53. 3-[N-(Cyclohexyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 149 °C, α20 D : - 60.4°, c = 1 % (Methanol).
  • 7.54. 3-[N-(Phenyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 161 °C, α20 D : -96.0°, c = 1 % (Methanol).
  • 7.55. 3-[N-(4'-Methyl-benzyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 135 °C, α20 D : -45.9°, c = 1% (Methanol).
  • 7.56. 3-[N-(4'-Nitro-benzyloxycarbonyl)-L-alanyloxy]-indol, gelbliche Kristalle, Schmp. 160 °C, α20 D : -29.4°, c = 1% (Methanol).
  • 7.57. 3-[N-(Benzylthiocarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 122 °C, α20 D: -77.8°, c = 1% (Methanol).
  • 7.58. 3-[N-(Methansulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 164-166 °C, α20 D : -54.0°, c = 1% (Methanol).
  • 7.59. 3-[N-(Benzylsulfonyl)-L-alanyloxy]-indol, farbloses, viskoses Öl, α20 D : - 54.8°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Essigester 2:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.40).
  • 7.60. 3-[N-(Benzolsulfonyl)-L-alanyloxy]-indol, farbloses, viskoses Öl, α20 D : -59.8°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Essigester 2:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.48).
  • 7.61. 3[N-(4'-Brom-benzolsulfonyl)-L-alanyloxy]-indol, gelbliches, amorphes Pulver, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.39).
  • 7.62. 3-[N-(4'-Nitro-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 136-137 °C, α20 D : -35.9°, c = 1% (Methanol).
  • 7.63. 3-[N-(4'-Acetylamino-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 162-163 °C,
    Figure imgb0029
    , c = 1% (Methanol).
  • 7.64. 3-[N-(4'-n-Butyl-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 105 °C,
    Figure imgb0030
    : -46.1°, c = 1% (Methanol).
  • 7.65. 3-[N-(4'-tert.-Butyl-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 140 °C,
    Figure imgb0031
    , c = 1% (Methanol).
  • 7.66. 3-[N-(4'-n-Octyl-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 57 °C,
    Figure imgb0032
    , c = 1% (Methanol).
  • 7.67. 3-[N-(4'-Hydroxy-benzolsulfonyl)-L-alanyloxy]-indol, viskoses, schwach rötliches Öl, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 1:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.62).
  • 7.68. 3-[N-(4'-Methoxy-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 126-128 °C,
    Figure imgb0033
    , c = 1% (Methanol).
  • 7.69. - 3-[N-(4'-Benzyloxy-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 112°C,
    Figure imgb0034
    , c = 1% (Methanol).
  • 7.70. 3-[N-(4'-(2"-Hydroxy-ethoxy)-benzolsulfonyl)-L-alanyloxy]-indol
  • 7.71. 3-[N-(4'-(3"-Oxa-5"-hydroxy-n-pentyloxy)-benzolsulfonyl)-L-alanyloxy]-indol farbloses, viskoses Öl,
    Figure imgb0035
    , c = 1% (Methanol) DC: Fertigplatte Kieselgel (Laufmittel: Toluol-Essigsäureethylester 1:10, Detektion: UV, NH3 (Gas), RF-Wert: 0.37
  • 7.72. 3-[N-(4'-(3",6"-Di-oxa-n-heptyloxy)-benzolsulfonyl)-L-alanyloxy]-indol, schwach rötliches, viskoses Öl, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.21
  • 7.73. 3-[N-(4'-(2"-Hydroxy-ethyl)-benzolsulfonyl)-L-alanyloxy]-indol, gelbliches, amorphes Pulver,
    Figure imgb0036
    , c = 1% (Methanol) DC: Fertigplatte, Kieselgel (Laufmittel: Toluol-Essigsäureethylester 1:2, Detektion: UV, NH3 (Gas), Rr-Wert: 0.26).
  • 7.74. 3-[N-(4'-(2"-{4"'-Nitro- benzyloxy}-ethyl)-benzolsulfonyl)-L-alanyloxy]-indol
  • 7.75. 3-[N-(4'-(2"-Chlor-ethyl)-benzolsulfonyl)-L-alanyloxy]-indol, schwach rötlicher, amorpher Schaum,
    Figure imgb0037
    , c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Essigester 5:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.20).
  • 7.76. 3-[N-(4'-Cyano-benzolsulfonyl)-L-alanyloxy]-indol farblose Kristalle, Schmp. 131 °C;
    Figure imgb0038
    , c = 1% (Dimethylformamid).
  • 7.77. 3-[N-(4'-Carboxy-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 143 °C,
    Figure imgb0039
    , c = 1% (Methanol).
  • 7.78. 3-[N-(4'-Benzyloxycarbonyl- benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 178 °C,
    Figure imgb0040
    , c = 1 % (Aceton).
  • 7.79. 3-[N-(4'-Carbamoyl-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 206 °C,
    Figure imgb0041
    , c = 1% (Aceton).
  • 7.80. 3-[N-(4'-(Dimethyl-carbamoyl)-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 170-172 °C,
    Figure imgb0042
    , c = 1 % (Dimethylformamid).
  • 7.81. 3-[N-Methyl-N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 82 °C,
    Figure imgb0043
    , c = 1% (Methanol).
  • 7.82. 3-[N-(2',4',6'-Trimethyl- benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 192-194 °C,
    Figure imgb0044
    , c = 1 % (Methanol).
  • 7.83. 3-[N-(Biphenyl-4'-sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 159°C,
    Figure imgb0045
    , c = 1% (Methanol).
  • 7.84. 3-[N-(Naphthalin-2'-sulfonyl)-L-alanyloxy]-indol, schwach rötliche Kristalle, Schmp. 103-105 °C, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.41).
  • 7.85. 3-[N-(4'-Acetylamino-naphthalin-1'-sulfonyl)-Lalanyloxy]-indol, farblose Kristalle, Schmp. 129-132 °C,
    Figure imgb0046
    , c = 1 % (Methanol).
  • 7.86. 3-[N-(5'-Dimethylamino-naphthalin-1'-sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 170 °C,
    Figure imgb0047
    , c = 1 % (Methanol).
  • 7.87. 3-[N-(Benzyloxycarbonyl)-L-alanyloxy]-benzo-[b]-thiophen, farbloses, viskoses Öl,
    Figure imgb0048
    , c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Dichlormethan, Detektion: UV, NaOH / K3Fe(CN)6, RF-Wert: 0.13).
  • 7.88. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-benzyl-indol
  • 7.89. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-phenyl-indol
In an analogous manner, the following substrates are obtained by reacting the appropriately substituted indoxyl compounds with the respective amino acids, with the above-mentioned 1-substituted 3-hydroxyindoles being formed as by-products in all cases (except 7.23. - 7.27.):
  • 7.1. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 123 ° C,
    Figure imgb0017
    (Methanol).
  • 7.2. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -4-methyl-indole, colorless crystals, mp. 113 ° C.,
    Figure imgb0018
    , c = 1% (methanol).
  • 7.3. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -5-methyl-indole, colorless crystals, mp. 143-144 ° C,
    Figure imgb0019
    , c = 1% (methanol).
  • 7.4. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -6-methyl-indole, colorless crystals, mp. 148 ° C,
    Figure imgb0020
    , c = 1% methanol).
  • 7.5. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -7-methyl-indole, colorless crystals, mp. 146 ° C,
    Figure imgb0021
    , c = 1% (methanol).
  • 7.6. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -4,7-dimethyl-indole, colorless crystals, mp. 121 ° C.,
    Figure imgb0022
    , c = 1% (methanol).
  • 7.7. 3- [N-Benzyloxycarbonyl) -L-alanyloxy] -4-chloroindole, colorless crystals, mp. 142-143 ° C,
    Figure imgb0023
    , c = 1% (methanol).
  • 7.8. 3- [N- (Benzyloxycarbonyl) -L-alanyloxyl-5-bromo-indole, colorless crystals, mp. 138 ° C.,
    Figure imgb0024
    , c = 1% (methanol).
  • 7.9. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -6-chloroindole, colorless crystals, mp. 170 ° C,
    Figure imgb0025
    , c = 1% (methanol).
  • 7.10. 3 [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-chloro-5-bromo-indole, colorless crystals, mp. 150-152 ° C,
    Figure imgb0026
    , c = 1% (methanol).
  • 7.11. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4,5,7-trichloroindole
  • December 7th 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-chloro-5-bromo-7-methyl-indole slightly beige crystals, mp. 143-145 ° C. TLC: finished plate silica gel, (eluent: toluene-dioxane 2: 1, detection: UV, NH 3 (gas), R F value: 0.56)
  • 7.13. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-hydroxy-indole
  • 7.14. 3- [N- (Benzyloxycarbonyl) -L-alanyloxy] -5-methoxy-indole
  • 7.15. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-benzyloxy-indole
  • 7.16. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-carboxy-indole
  • 7.17. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -4-benzyloxycarbonyl-indole
  • 7.18. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5- (carboxymethoxy) indole
  • 7.19. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5- (benzyloxy-carbonyl-methoxy) indole
  • 7.20. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -6-nitro-indole
  • 7.21. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -6-acetylamino-indole
  • 7.22. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] benzo [g] indole
  • 7.23. 1-methyl-3- [N- (benzyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, melting point 92 ° C.,
    Figure imgb0027
    , c = 1% (methanol).
  • 7.24. 1-benzyl-3- [N-toluene-4'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 149-152 ° C,
    Figure imgb0028
    , c = 1% (DMF).
  • 7.25 1-phenyl-3- [N- (toluene-4'-sulfonyl) -L-alanyloxyl] indole
  • 7.26. 1-acetyl-3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] indole
  • 7.27. 1-Benzoyl-3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp 155-156 ° C, α 20 D : -54.7 °, c = 1% (DMF ) .
  • 7.28. 3- [N- (Benzyloxycarbonyl) glycyloxy] indole, colorless crystals, mp 122-124 ° C.
  • 7.29. 3- [N- (Toluene-4'-sulfonyl) glycyloxy] indole, colorless crystals, mp 103-105 ° C.
  • 7.30. 3- [N- (toluene-2'-sulfonyl) -L-alanyloxy] indole colorless amorphous powder; α 20 D : -62.5 °, c = 1% (methanol) TLC: silica gel finished plate (eluent: toluene-dioxane 9: 1
  • Detection: UV, NH 3 (gas), R F value: 0.20) 7.31. 3- [N- (toluene-3'-sulfonyl) -L-alanyloxy] indole colorless crystals, mp 94 ° C; α 20 D : - 54.9 °, c = 1% (methanol)
  • 7.32. 3- [N- (Toluene-4'-sulfonyl) -D-alanyloxy] indole, colorless crystals, mp. 98 ° C, α 20 D + 53.1 °, c = 1% (methanol).
  • 7.33. 3- [N- (Benzyloxycarbonyl) -D, L-alanyloxy] indole, colorless crystals, mp 110-111 ° C.
  • 7.34. 3- [N- (Benzyloxycarbonyl) -L-valyloxy] indole, colorless crystals, mp. 64-65 ° C, α 20 D -41.1 °, c = 1% (methanol).
  • 7.35. 3- [N- (Benzyloxycarbonyl) -L-leucyloxyl-indole, colorless crystals, mp. 73-75 ° C, α 20 D -42.2 °, c = 1% (methanol).
  • 7.36. 3- [N- (Benzyloxycarbonyl) -L-isoleucyloxy] indole, colorless, amorphous powder, α 20 D -30.6 °, c = 1% (methanol), TLC: finished plate silica gel, (eluent: toluene-dioxane 2: 1 , Detection: UV, NH 3 (gas), R F value: 0.57).
  • 7.37. 3- [N- (Benzyloxycarbonyl) -L-phenylalanyloxy] indole, yellowish crystals, mp. 125 ° C, TLC: silica gel finished plate, (eluent: toluene-dioxane 9: 1, detection: UV, NH 3 (gas), RF value: 0.56).
  • 7.38. 3- [N- (toluene-4'-sulfonyl) -L-phenylalanyloxy] indole, colorless crystals, mp. 167-169 ° C, α 20 D : -34.4 °, c = 1% (methanol).
  • 7.39. 3- [N-acetyl-L-tyrosyloxy] indole
  • 7.40. 3- [N-benzoyl-L-tyrosyloxy] indole
  • 7.41. 3- [N- (Benzyloxycarbonyl) -L-tyrosyloxy] indole, colorless, amorphous foam, α 20 D : -22.6 °, c = 1% (methanol), TLC: finished plate silica gel, (eluent: toluene-dioxane 4: 1, detection: UV, NH 3 (gas), Rr value: 0.27).
  • 7.42. 3- [N- (Toluene-4'-sulfonyl) -L-tyrosyloxy] indole, colorless crystals, mp. 171 ° C, α 20 D : -28.3 °, c = 1% (methanol).
  • 7.43. 3- [N- (toluene-4'-sulfonyl) - O-acetyl-L-tyrosyloxy] indole, colorless crystals, mp. 168-170 ° C, α 20 D : - 24.1 °, c = 1% (dimethylformamide ).
  • 7.44. 3- [N- (Benzyloxycarbonyl) -L-alanyl-L-alanyloxy] indole, colorless crystals, mp. 144 ° C, α 20 D : -17.3 °, c = 1% (methanol).
  • 7.45. 3- [N- (Toluene-4'-sulfonyl) -D-alanyl-L-alanyloxy] indole, yellowish, amorphous foam, α 20 D : + 5.8 °, c = 1% (methanol), TLC: finished plate silica gel , (Eluent: toluene-dioxane 4: 1, detection: UV, NH 3 (gas), RF value: 0.19).
  • 7.46. 3- [N- (Benzyloxycarbonyl) -L-alanyl-L-alanyl-L-alanyloxy] indole, colorless crystals, mp. 156 ° C, α 20 D : -39.5 °, c = 1% (methanol).
  • 7.47. 3- [N- (Toluene-4'-sulfonyl) -D-alanyl-D-alanyl-L-alanyloxy] indole, colorless crystals, mp. 216 ° C, α 20 D : + 53.8 °, c = 1% (Methanol).
  • 7.48. 3- [N-acetyl-L-alanyloxy] indole, colorless, amorphous foam, α 20 D : -12.5 °, c = 1% (methanol), TLC: finished plate silica gel, (mobile phase: ethyl acetate-dichloromethane 10: 1, Detection: UV, NH 3 (gas), RF value: 0.33).
  • 7.49. 3- [N-succinyl-L-alanyloxy] indole, colorless crystals, mp. 142 ° C, α 20 D : - 63.9 °, c = 1% (methanol).
  • 7.50. 3- [N-Benzoyl-D, L-alanyloxy] indole, colorless crystals, mp. 171 ° C.
  • 7.51. 3- [N-phthaloyl-L-alanyloxy] indole, colorless crystals, mp. 58 ° C, α 20 D : -26.3 °, c = 1% (methanol).
  • 7.52. 3- [N- (Ethoxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 96 ° C, α 20 D : -68.9 °, c = 1% (methanol).
  • 7.53. 3- [N- (Cyclohexyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 149 ° C, α 20 D : - 60.4 °, c = 1% (methanol).
  • 7.54. 3- [N- (Phenyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 161 ° C, α 20 D : -96.0 °, c = 1% (methanol).
  • 7.55. 3- [N- (4'-Methyl-benzyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 135 ° C, α 20 D : -45.9 °, c = 1% (methanol).
  • 7.56. 3- [N- (4'-Nitro-benzyloxycarbonyl) -L-alanyloxy] indole, yellowish crystals, mp. 160 ° C, α 20 D : -29.4 °, c = 1% (methanol).
  • 7.57. 3- [N- (Benzylthiocarbonyl) -L-alanyloxy] indole, colorless crystals, mp 122 ° C, α 20 D : -77.8 °, c = 1% (methanol).
  • 7.58. 3- [N- (methanesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 164-166 ° C, α 20 D : -54.0 °, c = 1% (methanol).
  • 7.59. 3- [N- (Benzylsulfonyl) -L-alanyloxy] indole, colorless, viscous oil, α 20 D : - 54.8 °, c = 1% (methanol), TLC: finished plate silica gel, (mobile phase: toluene-ethyl acetate 2: 1, detection: UV, NH 3 (gas), RF value: 0.40).
  • 7.60. 3- [N- (benzenesulfonyl) -L-alanyloxy] indole, colorless, viscous oil, α 20 D : -59.8 °, c = 1% (methanol), TLC: finished plate silica gel, (eluent: toluene-ethyl acetate 2: 1, detection: UV, NH 3 (gas), RF value: 0.48).
  • 7.61. 3 [N- (4'-bromo-benzenesulfonyl) -L-alanyloxy] indole, yellowish, amorphous powder, TLC: silica gel finished plate, (mobile phase: toluene-dioxane 4: 1, Detection: UV, NH 3 (gas), RF value: 0.39).
  • 7.62. 3- [N- (4'-Nitro-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp 136-137 ° C, α 20 D : -35.9 °, c = 1% (methanol).
  • 7.63. 3- [N- (4'-Acetylamino-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp 162-163 ° C,
    Figure imgb0029
    , c = 1% (methanol).
  • 7.64. 3- [N- (4'-n-Butyl-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 105 ° C.,
    Figure imgb0030
    : -46.1 °, c = 1% (methanol).
  • 7.65. 3- [N- (4'-tert-butyl-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 140 ° C.,
    Figure imgb0031
    , c = 1% (methanol).
  • 7.66. 3- [N- (4'-n-octyl-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 57 ° C.,
    Figure imgb0032
    , c = 1% (methanol).
  • 7.67. 3- [N- (4'-Hydroxy-benzenesulfonyl) -L-alanyloxy] indole, viscous, slightly reddish oil, TLC: finished plate silica gel, (eluent: toluene-dioxane 1: 1, detection: UV, NH 3 (gas ), R F value: 0.62).
  • 7.68. 3- [N- (4'-methoxy-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 126-128 ° C,
    Figure imgb0033
    , c = 1% (methanol).
  • 7.69. 3- [N- (4'-benzyloxy-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp 112 ° C.,
    Figure imgb0034
    , c = 1% (methanol).
  • 7.70. 3- [N- (4 '- (2 "-hydroxy-ethoxy) -benzenesulfonyl) -L-alanyloxy] indole
  • 7.71. 3- [N- (4 '- (3 "-Oxa-5" -hydroxy-n-pentyloxy) benzenesulfonyl) -L-alanyloxy] indole colorless, viscous oil,
    Figure imgb0035
    , c = 1% (methanol) TLC: silica gel finished plate (eluent: toluene-ethyl acetate 1:10, detection: UV, NH 3 (gas), RF value: 0.37
  • 7.72. 3- [N- (4 '- (3 ", 6" -Di-oxa-n-heptyloxy) -benzenesulfonyl) -L-alanyloxy] -indole, slightly reddish, viscous oil, TLC: finished plate silica gel, (eluent: toluene -Dioxane 4: 1, detection: UV, NH 3 (gas), RF value: 0.21
  • 7.73. 3- [N- (4 '- (2 "-hydroxy-ethyl) -benzenesulfonyl) -L-alanyloxy] indole, yellowish, amorphous powder,
    Figure imgb0036
    , c = 1% (methanol) TLC: finished plate, silica gel (mobile phase: toluene-ethyl acetate 1: 2, detection: UV, NH 3 (gas), Rr value: 0.26).
  • 7.74. 3- [N- (4 '- (2 "- {4"' - nitrobenzyloxy} ethyl) benzenesulfonyl) -L-alanyloxy] indole
  • 7.75. 3- [N- (4 '- (2 "-chloro-ethyl) -benzenesulfonyl) -L-alanyloxy] indole, slightly reddish, amorphous foam,
    Figure imgb0037
    , c = 1% (methanol), TLC: silica gel finished plate, (mobile phase: toluene-ethyl acetate 5: 1, detection: UV, NH3 (gas), R F value: 0.20).
  • 7.76. 3- [N- (4'-Cyano-benzenesulfonyl) -L-alanyloxy] indole colorless crystals, mp 131 ° C;
    Figure imgb0038
    , c = 1% (dimethylformamide).
  • 7.77. 3- [N- (4'-carboxy-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 143 ° C.,
    Figure imgb0039
    , c = 1% (methanol).
  • 7.78. 3- [N- (4'-Benzyloxycarbonylbenzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 178 ° C,
    Figure imgb0040
    , c = 1% (acetone).
  • 7.79. 3- [N- (4'-Carbamoyl-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 206 ° C.,
    Figure imgb0041
    , c = 1% (acetone).
  • 7.80. 3- [N- (4 '- (Dimethyl-carbamoyl) -benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 170-172 ° C,
    Figure imgb0042
    , c = 1% (dimethylformamide).
  • 7.81. 3- [N-methyl-N- (toluene-4'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 82 ° C.,
    Figure imgb0043
    , c = 1% (methanol).
  • 7.82. 3- [N- (2 ', 4', 6'-trimethylbenzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 192-194 ° C,
    Figure imgb0044
    , c = 1% (methanol).
  • 7.83. 3- [N- (Biphenyl-4'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 159 ° C.,
    Figure imgb0045
    , c = 1% (methanol).
  • 7.84. 3- [N- (naphthalene-2'-sulfonyl) -L-alanyloxy] indole, slightly reddish crystals, mp. 103-105 ° C, TLC: finished plate silica gel, (eluent: toluene-dioxane 4: 1, detection: UV, NH 3 (gas), R F value: 0.41).
  • 7.85. 3- [N- (4'-acetylamino-naphthalene-1'-sulfonyl) -lalanyloxy] indole, colorless crystals, mp. 129-132 ° C,
    Figure imgb0046
    , c = 1% (methanol).
  • 7.86. 3- [N- (5'-Dimethylamino-naphthalene-1'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 170 ° C.,
    Figure imgb0047
    , c = 1% (methanol).
  • 7.87. 3- [N- (benzyloxycarbonyl) -L-alanyloxy] benzo [b] thiophene, colorless, viscous oil,
    Figure imgb0048
    , c = 1% (methanol), TLC: silica gel finished plate, (eluent: dichloromethane, detection: UV, NaOH / K 3 Fe (CN) 6 , R F value: 0.13).
  • 7.88. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-benzyl-indole
  • 7.89. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-phenyl-indole

Beispiel 8Example 8 3-[N-(tert.-Butyloxycarbonyl)-L-alanyloxy]-indol3- [N- (tert-Butyloxycarbonyl) -L-alanyloxy] indole

Zur Umsetzung nach dem Carbodimid-Verfahren werden 3.23 g (0.017 mol) N-tert.-Butyloxycarbonyl-L-alanin und 2.27 g (0.017 mol) Indoxyl in 100 ml abs. Dioxan-Dichlormethan 1:1 gelöst. Nach Zugabe einer Lösung von 3.87 g (0.019 mol) Dicyclohexylcarbodiimid (DCC) in 20 ml abs. Dioxan rührt man unter Wasser- und Sauerstoffausschluss 68 h bei Raumtemperatur. Der abgeschiedene N,N'-Dicyclohexylharnstoff wird abgesaugt, das Lösungsmittel im Vakuum abdestilliert und der Rückstand in ca. 100 ml Essigsäureethylester aufgenommen. Nach Absaugen von weiterem ausgefallenem N,N'-Dicyclohexylharnstoff wird die klare Essigesterlösung nacheinander je zweimal mit 30 ml 1 N Zitronensäure, 20 ml Wasser, 50 ml 5-10-proz. Natriumhydrogencarbonatlösung und 25 ml Wasser gewaschen. Nach Trocknen über Natriumsulfat wird die Essigesterphase im Vakuum eingeengt. Der amorphe Rückstand wird säulenchromatographisch an Kieselgel mit einem Toluol-Dioxan-Gemisch (9:1) gereinigt.For the reaction according to the carbodimide process, 3.23 g (0.017 mol) of N-tert-butyloxycarbonyl-L-alanine and 2.27 g (0.017 mol) of indoxyl in 100 ml of abs. Dioxane-dichloromethane dissolved 1: 1. After adding a solution of 3.87 g (0.019 mol) of dicyclohexylcarbodiimide (DCC) in 20 ml of abs. Dioxane is stirred with the exclusion of water and oxygen for 68 h at room temperature. The deposited N, N'-dicyclohexylurea is filtered off with suction, the solvent is distilled off in vacuo and the residue is taken up in about 100 ml of ethyl acetate. After suctioning off further precipitated N, N'-dicyclohexylurea, the clear ethyl acetate solution is in succession twice with 30 ml of 1 N citric acid, 20 ml of water, 50 ml of 5-10 percent. Washed sodium bicarbonate solution and 25 ml of water. After drying over sodium sulfate, the ethyl acetate phase is concentrated in vacuo. The amorphous residue is purified by column chromatography on silica gel using a toluene / dioxane mixture (9: 1).

Nach Einengen der gesammelten Fraktionen im Vakuum und Umkristallisieren des Rückstandes aus Essigester-Ether (1:10) erhält man

  • 1.04 g (20%) 3-[N-(tert. -Butyloxycarbonyl)-L-alanyloxy]-indol,
  • farblose Kristalle, Schmp. 158 °C,
  • Figure imgb0049
    , c = 1% (Methanol).
After concentrating the collected fractions in vacuo and recrystallizing the residue from ethyl acetate-ether (1:10)
  • 1.04 g (20%) 3- [N- (tert -Butyloxycarbonyl) -L-alanyloxy] indole,
  • colorless crystals, mp. 158 ° C,
  • Figure imgb0049
    , c = 1% (methanol).

Als Nebenprodukt entsteht auch bei dieser Umsetzung das in 1-Stellung substituierte 3-Hydroxy-indol (s. Beispiel 7).This reaction also produces the 3-hydroxy-indole substituted in the 1-position as a by-product (see Example 7).

In analoger Weise erhält man durch Umsetzung der entsprechend substituierten Indoxyl-Verbindungen mit den jeweiligen Aminosäuren die folgenden Substrate, wobei auch hier in allen Fällen als Nebenprodukte die entsprechenden in 1-Stellung substituierten 3-Hydroxy-indole entstehen:

  • 8.1. 3-[N-Formyl-L-alanyloxy]-indol, farblose Kristalle, Schmp. 121-122 °C,
    Figure imgb0050
    , c = 1 % (Methanol).
  • 8.2. 3-[N-(4 '-Methoxy-benzyloxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 92 °C,
    Figure imgb0051
    , c = 1% (Methanol).
  • 8.3. 3-[N-(N-(Piperidino)-oxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 104 °C,
    Figure imgb0052
    , c = 1% (Methanol).
  • 8.4. 3-[N-(Thienyl-(2')-methoxycarbonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 134 °C,
    Figure imgb0053
    , c = 1 % (Methanol).
  • 8.5. 3-[N-(Chinolin-8'-sulfonyl)-L-alanyloxy]-indol, amorphes, schwach rötliches Pulver, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.23).
  • 8.6. 3-[N-(Diphenylcarbamoyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 188-190 °C, α20 D : +22.2°, c = 1% (Pyridin).
The following substrates are obtained in an analogous manner by reacting the correspondingly substituted indoxyl compounds with the respective amino acids, the corresponding 3-hydroxyindoles substituted in the 1-position also being formed here in all cases:
  • 8.1. 3- [N-formyl-L-alanyloxy] indole, colorless crystals, mp. 121-122 ° C,
    Figure imgb0050
    , c = 1% (methanol).
  • 8.2. 3- [N- (4 '-Methoxy-benzyloxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 92 ° C,
    Figure imgb0051
    , c = 1% (methanol).
  • 8.3. 3- [N- (N- (Piperidino) -oxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 104 ° C,
    Figure imgb0052
    , c = 1% (methanol).
  • 8.4. 3- [N- (Thienyl- (2 ') - methoxycarbonyl) -L-alanyloxy] indole, colorless crystals, mp. 134 ° C,
    Figure imgb0053
    , c = 1% (methanol).
  • 8.5. 3- [N- (Quinoline-8'-sulfonyl) -L-alanyloxy] indole, amorphous, slightly reddish powder, TLC: silica gel finished plate, (eluent: toluene-dioxane 4: 1, detection: UV, NH 3 (gas ), RF value: 0.23).
  • 8.6. 3- [N- (Diphenylcarbamoyl) -L-alanyloxy] indole, colorless crystals, mp. 188-190 ° C, α 20 D : + 22.2 °, c = 1% (pyridine).

Beispiel 9Example 9 3-[ N-(Furyl-(2')-methoxycarbonyl)-L-alanyl- oxy]-indol3- [N- (furyl- (2 ') methoxycarbonyl) -L-alanyloxy] indole

Zur Umsetzung nach dem Aktivester-Verfahren werden 4.26g (0.02 mol) N-(Furyl-(2')-methoxycarbonyl)-L-alanin und 5.4g (0.04 mol) N-Hydroxy-benzotriazol in 50 ml abs. Tetrahydrofuran (THF) gelöst, auf 0 °C abgekühlt und mit einer Lösung von 4.4 g (0.022 mol) Dicyclohexylcarbodiimid (DCC) in 10 ml abs. THF versetzt. Zur Bildung des Aktivesters rührt man das Reaktionsgemisch 1.5 h bei 0 °C, dann 2 h bei Raumtemperatur. Darauf fügt man unter Sauerstoff- und Wasserausschluss 2.66 g (0.02 mol) Indoxyl und 2.77 ml (0.04 mol) abs. Triethylamin zu. Das Gemisch wird 18 h bei Raumtemperatur gerührt. Der gebildete N,N'-Dicyclohexylharnstoff wird abgesaugt, das Lösungsmittel wird im Vakuum abdestilliert und der Rückstand wird wie in Beispiel 7 beschrieben aufgearbeitet. Das amorphe Rohprodukt wird dann säulenchromatographisch an einer Kieselgelsäule mit einem Toluol-Essigester-Gemisch (5:1) gereinigt. Nach Einengen der entsprechenden gesammelten Fraktionen und Umkristallisation aus Essigester-Petrolether 1:1 ergeben sich

  • 3.0 g (45.7%) 3-[N-(Furyl-(2')-methoxycarbonyl)-L-alanyloxy]-indol,
  • farblose Kristalle, Schmp. 129 °C,
  • Figure imgb0054
    , c = 1 % (Methanol).
For the reaction according to the active ester method, 4.26 g (0.02 mol) of N- (furyl- (2 ') - methoxycarbonyl) -L-alanine and 5.4 g (0.04 mol) of N-hydroxy-benzotriazole in 50 ml abs. Dissolved tetrahydrofuran (THF), cooled to 0 ° C and with a solution of 4.4 g (0.022 mol) of dicyclohexylcarbodiimide (DCC) in 10 ml abs. THF offset. To form the active ester, the reaction mixture is stirred at 0 ° C. for 1.5 h, then at room temperature for 2 h. Then add 2.66 g (0.02 mol) indoxyl and 2.77 ml (0.04 mol) abs while excluding oxygen and water. Triethylamine too. The mixture is stirred at room temperature for 18 h. The N, N'-dicyclohexylurea formed is filtered off with suction, the solvent is distilled off in vacuo and the residue is worked up as described in Example 7. The amorphous crude product is then purified by column chromatography on a silica gel column using a toluene / ethyl acetate mixture (5: 1). After concentration of the corresponding collected fractions and recrystallization from ethyl acetate-petroleum ether 1: 1
  • 3.0 g (45.7%) 3- [N- (furyl- (2 ') methoxycarbonyl) -L-alanyloxy] indole,
  • colorless crystals, mp. 129 ° C,
  • Figure imgb0054
    , c = 1% (methanol).

In analoger Weise erhält man durch Reaktion der entsprechend substituierten Aminosäuren oder Peptide mit den jeweiligen Indoxyl-Verbindungen die folgenden Substanzen:

  • 9.1. 3-[N-(Toluol-4'-sulfonyl-L-valyloxy]-indol, farblose Kristalle, Schmp. 125-127 °C,
    Figure imgb0055
    , c = 1% (Methanol).
  • 9.2. 3-[N-(4'-Dimethylamino-benzolsulfonyl)-L-alanyloxy]-indol, amorphes, schwach rötliches Pulver, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 3:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.25).
  • 9. 3. 3-[N-(4'-Acetyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 9.4. 3-[N-(4'-Methoxycarbonyl-benzolsulfo- nyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 140-141 °C,
    Figure imgb0056
    , c = 1 % (Methanol).
  • 9.5. 3-[N-(4'-Carboxymethyl-benzolsulfonyl)-L-alanyloxy]-indol, amorpher, farbloser Schaum, α20 D : -82.1°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Isopropanol-Essigsäure-n-butylester-Wasser 5:3:2, Detektion: UV, NH3 (Gas), RFWert: 0.68).
  • 9.6. 3-[N-(4'Carboxymethoxy-benzolsulfonyl)-L-alanyloxy]-indol, amorpher, farbloser Schaum, α20 D : -47.7°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan-Eisessig 6:2:1, Detektion: UV, NH3 (Gas), RFWert: 0.27).
  • 9.7. 3-[N-(4'-Carboxymethylamino- benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 151-153 °C α20 D : -71.5°, c = 1% (Methanol).
  • 9.8. 3-[N'-(4'-(Benzyloxycarbonyl- methylamino)-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 110-113 °C, α20 D : - 60.0°, c = 1 % (Methanol).
  • 9.9. 3-[N-(4'-Fluor-benzolsulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 94-95 °C, α20 D : -48.5°, c = 1% (Methanol).
  • 9.10. 3-[N-(4'-Fluorsulfonyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 9.11. 3-[N-(4'-Sulfamoyl-benzolsulfonyl)-L-alanyloxy]-indol
  • 9.12. 3-[N-Acetyl-N-(toluol-4'-sulfonyl)-L-alanyloxy]-indol, farbloses, amorphes Pulver, α20 D : -10.6°, c = 1% (Methanol), DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 9:1, Detektion: UV, NH3 (Gas), RFWert: 0.17).
  • 9.13. 3-[N-(Pyridin-3'- sulfonyl)-L-alanyloxy]-indol, farblose Kristalle, Schmp. 155-157 °C, α20 D : -55.1°, c = 1% (Methanol).
  • 9.14. 3-[N-(5',5'-Dimethyl-3'-oxo- cyclohexen-1'-yl)-L-alanyloxy]-indol. farblose Kristalle, Schmp. 154°C, α20 D : -272.2°, c = 1% (Methanol).
  • 9.15. 3-[N-(Di-(4'-nitrobenzyl)-phosphoryl)-L-alanyloxy]-indol
  • 9.16. 3-[N-(Di-(4'-brombenzyl)-phosphoryl)-L-alanyloxy]-indol
  • 9.17. 3-[N-(Toluol-4'-sulfonyl)-L-alanyloxy]-5-methoxy-indol farbloses, viskoses Öl; α20 D : - 46.8°, c = 1% (Methanol), DC:Fertigplatte, Kieselgel (Laufmittel: Toluol-Essigsäureethylester 2:1 Detektion: UV, NH3 (Gas), RFWert: 0.45).
The following substances are obtained in an analogous manner by reacting the correspondingly substituted amino acids or peptides with the respective indoxyl compounds:
  • 9.1. 3- [N- (toluene-4'-sulfonyl-L-valyloxy] indole, colorless crystals, mp 125-127 ° C,
    Figure imgb0055
    , c = 1% (methanol).
  • 9.2. 3- [N- (4'-Dimethylamino-benzenesulfonyl) -L-alanyloxy] indole, amorphous, slightly reddish powder, TLC: finished plate silica gel, (eluent: toluene-dioxane 3: 1, detection: UV, NH 3 (gas ), RF value: 0.25).
  • 9. 3. 3- [N- (4'-Acetyl-benzenesulfonyl) -L-alanyloxy] indole
  • 9.4. 3- [N- (4'-methoxycarbonyl-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 140-141 ° C,
    Figure imgb0056
    , c = 1% (methanol).
  • 9.5. 3- [N- (4'-Carboxymethyl-benzenesulfonyl) -L-alanyloxy] indole, amorphous, colorless foam, α 20 D : -82.1 °, c = 1% (methanol), TLC: finished plate silica gel, (eluent: Isopropanol-n-butyl ester water 5: 3: 2, detection: UV, NH 3 (gas), R F value: 0.68).
  • 9.6. 3- [N- (4'Carboxymethoxy-benzenesulfonyl) -L-alanyloxy] indole, amorphous, colorless foam, α 20 D : -47.7 °, c = 1% (methanol), TLC: silica gel ready plate, (eluent: toluene -Dioxane-glacial acetic acid 6: 2: 1, detection: UV, NH 3 (gas), RF value: 0.27).
  • 9.7. 3- [N- (4'-Carboxymethylamino-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp 151-153 ° C α 20 D : -71.5 °, c = 1% (methanol).
  • 9.8. 3- [N '- (4' - (Benzyloxycarbonyl-methylamino) -benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 110-113 ° C, α 20 D : - 60.0 °, c = 1% ( Methanol).
  • 9.9. 3- [N- (4'-Fluoro-benzenesulfonyl) -L-alanyloxy] indole, colorless crystals, mp. 94-95 ° C, α 20 D : -48.5 °, c = 1% (methanol).
  • 9.10. 3- [N- (4'-Fluorosulfonyl-benzenesulfonyl) -L-alanyloxy] indole
  • 9.11. 3- [N- (4'-Sulfamoyl-benzenesulfonyl) -L-alanyloxy] indole
  • 9.12. 3- [N-acetyl-N- (toluene-4'-sulfonyl) -L-alanyloxy] indole, colorless, amorphous powder, α 20 D : -10.6 °, c = 1% (methanol), TLC: finished plate silica gel , (Eluent: toluene-dioxane 9: 1, detection: UV, NH 3 (gas), R F value: 0.17).
  • 9.13. 3- [N- (pyridine-3'-sulfonyl) -L-alanyloxy] indole, colorless crystals, mp 155-157 ° C, α 20 D : -55.1 °, c = 1% (methanol).
  • 9.14. 3- [N- (5 ', 5'-Dimethyl-3'-oxocyclohexen-1'-yl) -L-alanyloxy] indole. colorless crystals, mp. 154 ° C, α 20 D : -272.2 °, c = 1% (methanol).
  • 9.15. 3- [N- (Di- (4'-nitrobenzyl) phosphoryl) -L-alanyloxy] indole
  • 9.16. 3- [N- (Di- (4'-bromobenzyl) phosphoryl) -L-alanyloxy] indole
  • 9.17. 3- [N- (toluene-4'-sulfonyl) -L-alanyloxy] -5-methoxy-indole colorless, viscous oil; α 20 D : - 46.8 °, c = 1% (methanol), TLC: finished plate, silica gel (eluent: toluene-ethyl acetate 2: 1 detection: UV, NH 3 (gas), R F value: 0.45).

Beispiel 10Example 10 3-[ N-(3',6'-Dioxa-n-heptyloxy-carbonyl)-L-alanyl- oxy]-indol3- [N- (3 ', 6'-Dioxa-n-heptyloxycarbonyl) -L-alanyloxy] indole

Zur Umsetzung nach dem Mischanhydrid-Verfahren werden 3.52 g (0.015 mol) N-(3,6-Dioxa-n-heptyloxy-carbonyl)-L-alanin in 35 ml abs. Tetrahydrofuran (THF) gelöst. Nach Zugabe von 2.1 ml (0.015 mol) Triethylamin wird das Gemisch auf -15°C abgekühlt und dann zur Bildung des Mischanhydrids mit 1.43 ml (0.015 mol) Chlorameisensäureethylester versetzt. Nach 1 h Rühren bei -15 °C fügt man unter Sauerstoff- und Wasserausschluss eine auf -15 °C gekühlte Lösung von 2.00 g (0.015 mol) Indoxyl in 20 ml abs. THF zu. Das Gemisch wird weitere 2 h bei -15 °C bis - 20 °C gerührt und dann über Nacht im Kühlschrank belassen. Das gebildete Triethylaminhydrochlorid wird abgesaugt, das Lösungsmittel wird im Vakuum abgezogen und der Rückstand wird wie in Beispiel 7 beschrieben aufgearbeitet. Das amorphe Rohprodukt wird dann säulenchromatographisch an Kieselgel zunächst mit einem Methylenchlorid-Methanol-Gemisch (95:5) und dann mit einem Toluol-Methylethylketon-Gemisch (1:2) gereinigt. Nach Behandeln der gesammelten Fraktionen mit Aktivkohle und Abziehen des Lösungsmittels ergeben sich

  • 0.51 g (9.5%) 3-[N-(3',6'-Dioxa-n-heptyloxy- carbonyl)-L alanyloxy]-indol,
  • farbloses, viskoses Öl,
  • α20 D : -40.4°, c = 1% (Methanol),
  • DC: Fertigplatte Kieselgel,
  • (Laufmittel: Toluol-Methylethylketon 1:2,
  • Detektion: UV, NH3 (Gas),
  • RF-Wert: 0.54).
For the reaction according to the mixed anhydride method, 3.52 g (0.015 mol) of N- (3,6-dioxa-n-heptyloxy-carbonyl) -L-alanine in 35 ml abs. Tetrahydrofuran (THF) dissolved. After adding 2.1 ml (0.015 mol) of triethylamine, the mixture is cooled to -15 ° C. and then 1.43 ml (0.015 mol) of ethyl chloroformate are added to form the mixed anhydride. After stirring for 1 h at -15 ° C, a solution of 2.00 g (0.015 mol) indoxyl in 20 ml abs, cooled to -15 ° C, is added with the exclusion of oxygen and water. THF too. The mixture is stirred for a further 2 h at -15 ° C to - 20 ° C and then left in the refrigerator overnight. The triethylamine hydrochloride formed is filtered off, the solvent is removed in vacuo and the residue is worked up as described in Example 7. The amorphous crude product is then purified by column chromatography on silica gel first with a methylene chloride-methanol mixture (95: 5) and then with a toluene-methyl ethyl ketone mixture (1: 2). After treating the collected fractions with activated carbon and removing the solvent
  • 0.51 g (9.5%) 3- [N- (3 ', 6'-dioxa-n-heptyloxycarbonyl) -L alanyloxy] indole,
  • colorless, viscous oil,
  • α 20 D : -40.4 °, c = 1% (methanol),
  • DC: finished plate silica gel,
  • (Eluent: toluene-methyl ethyl ketone 1: 2,
  • Detection: UV, NH 3 (gas),
  • R F value: 0.54).

In analoger Weise erhält man durch Reaktion der entsprechend substituierten Aminosäuren mit den jeweiligen Indoxyl-Verbindungen die folgenden Substanzen:

  • 10.1. 3-[N-(2'-Nitro-benzolsulfenyl)-L-alanyloxy]-indol, gelbe Kristalle, Schmp. 133-134°C,
    Figure imgb0057
    , c = 1% (Methanol).
  • 10.2. 3-[N-(1'-Methyl-2'-benzoyl- vinyl)-L-alanyloxy]-indol, schwach rötliche Kristalle, Schmp. 130-133 °C, DC: Fertigplatte Kieselgel, (Laufmittel: Toluol-Dioxan 4:1, Detektion: UV, NH3 (Gas), RF-Wert: 0.45).
The following substances are obtained in an analogous manner by reaction of the correspondingly substituted amino acids with the respective indoxyl compounds:
  • 10.1. 3- [N- (2'-Nitro-benzenesulfenyl) -L-alanyloxy] indole, yellow crystals, mp. 133-134 ° C,
    Figure imgb0057
    , c = 1% (methanol).
  • 10.2. 3- [N- (1'-Methyl-2'-benzoyl-vinyl) -L-alanyloxy] indole, slightly reddish crystals, mp. 130-133 ° C, TLC: finished plate silica gel, (eluent: toluene-dioxane 4 : 1, detection: UV, NH 3 (gas), R F value: 0.45).

Claims (6)

1. Diagnostic agent for the detection of proteolytic enzymes, consisting of an absorbent carrier, a film layer, a powder mixture, a lyophilisate, a solution or a reagent tablet, containing one or more chromogens and a suitable buffer substance, characterised in that as chromogens there are used indoxyl- and/or thioindoxylamino acid esters and/or peptide esters of the general formula I
Figure imgb0068
in which
R1, R2, R3, R4, which can be the same or different, each signify hydrogen or halogen, a lower alkyl, lower alkoxy, aryl, aralkyl, aralkoxy, a hydroxyl, a carboxy, a carboxy lower alkoxy, an aralkoxycarbonyl, an aralkyloxycarbonyl lower alkoxy, a nitro or a lower acylamino group or two neighbouring substituents a benzo-annellated radical possibly substituted by halogen,
X a sulphur atom or an imino group possibly substituted by a lower alkyl, an aryl, an aralkyl or an acyl radical,
A an amino acid or a peptide residue,
B a nitrogen protective group conventional in peptide chemistry or derived therefrom.
2. Diagnostic agent according to claim 1, characterised in that conventionally used adjuvants are additionally added.
3. Diagnostic agent according to claim 2, characterised in that wetting agents, oxidation agents, film formers, galenical additives and/or structural formers are employed as additional ajuvants.
4. Use of indoxyl- and/or thioindoxyl-amino acid esters and/or peptide esters of the general formula I
Figure imgb0069
in which
R1, R2, R3, R4, which can be the same or different, each signify hydrogen or halogen, a lower alkyl, lower alkoxy, aryl, aralkyl, aralkoxy, a hydroxyl, a carboxy, a carboxy lower alkoxy, an aralkoxycarbonyl, an aralkyloxycarbonyl lower alkoxy, a nitro or a lower acylamino group of two neighbouring substituents a benzo-annellated radical possibly substituted by halogen,
X a sulphur atom or an imino group possibly substituted by a lower alkyl, an aryl, an aralkyl or an acyl radical,
A an amino acid or a peptide residue,
B a nitrogen protective group conventional in peptide chemistry or derived therefrom, for the production of diagnostic agents for the detection of proteolytic enzymes.
5. Indoxyl and thioindoxyl-amino acid esters and peptide esters of the general formula I
Figure imgb0070
in which
Ri, R2, R3, R4, which can be the same or different, each signify hydrogen or halogen, a lower alkyl, lower alkoxy, aryl, aralkyl, aralkoxy, a hydroxyl, a carboxy, a carboxy lower alkoxy, an aralkoxycarbonyl, an aralkyloxycarbonyl lower alkoxy, a nitro or a lower acylamino group or two neighbouring substituents a benzo-annellated radical possibly substituted by halogen,
X a sulphur atom or an imino group possibly substituted by a lower alkyl, an aryl, an aralkyl or an acyl radical,
A an amino acid or a peptide residue,
B a nitrogen protective group conventional in peptide chemistry or derived therefrom.
6. Process for the preparation of indoxyl- and thioindoxyl-amino acid esters and peptide esters of the general formula I
Figure imgb0071
in which
R1, R2, R3, R4, which can be the same or different, each signify hydrogen or halogen, a lower alkyl, lower alkoxy, aryl, aralkyl, aralkoxy, a hydroxyl, a carboxy, a carboxy lower alkoxy, an aralkoxycarbonyl, an aralkyloxycarbonyl lower alkoxy, a nitro or a lower acylamino group or two neighbouring substituents a benzo-annellated radical possibly substituted by halogen,
X a sulphur atom or an imino group possibly substituted by a lower alkyl, an aryl, an aralkyl or an acyl radical,
A an amino acid or a peptide residue,
B a nitrogen protective group conventional in peptide chemistry or derived therefrom,

characterised in that, in per se known manner, one reacts compounds of the general formula II
Figure imgb0072
in which
R1, R2, R3, R4 and X have the above-given meaning, with amino acids and peptides of the general formula III
Figure imgb0073
in which
A and B have the above-given meaning,
or with reactive derivatives thereof.
EP79105184A 1978-12-20 1979-12-14 Diagnostic means for the detection of proteolytic enzymes and indoxyl or thioindoxyl ester chromogens useful therefor, process for their preparation and their use in the preparation of diagnostic means Expired EP0012957B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT79105184T ATE230T1 (en) 1978-12-20 1979-12-14 DIAGNOSTIC MEANS FOR DETECTING PROTEOLYTIC ENZYMES AND AS CHROMOGENIC INDOXYL- OR THIOINDOXYLESTERS, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF DIAGNOSTIC AGENTS.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2854987A DE2854987A1 (en) 1978-12-20 1978-12-20 DIAGNOSTIC AGENTS FOR DETECTING PROTEOLYTIC ENZYMS AND CHROMOGENS SUITABLE FOR THIS
DE2854987 1978-12-20

Publications (2)

Publication Number Publication Date
EP0012957A1 EP0012957A1 (en) 1980-07-09
EP0012957B1 true EP0012957B1 (en) 1981-09-16

Family

ID=6057730

Family Applications (1)

Application Number Title Priority Date Filing Date
EP79105184A Expired EP0012957B1 (en) 1978-12-20 1979-12-14 Diagnostic means for the detection of proteolytic enzymes and indoxyl or thioindoxyl ester chromogens useful therefor, process for their preparation and their use in the preparation of diagnostic means

Country Status (20)

Country Link
US (1) US4278763A (en)
EP (1) EP0012957B1 (en)
JP (1) JPS593475B2 (en)
AR (1) AR223505A1 (en)
AT (1) ATE230T1 (en)
AU (1) AU515190B2 (en)
BR (1) BR7908306A (en)
CA (1) CA1130801A (en)
CS (1) CS245763B2 (en)
DD (1) DD147845A5 (en)
DE (2) DE2854987A1 (en)
DK (1) DK155318C (en)
ES (1) ES486932A1 (en)
FI (1) FI77229C (en)
HU (1) HU180431B (en)
PL (1) PL127198B1 (en)
PT (1) PT70608A (en)
SU (2) SU1184444A3 (en)
YU (1) YU311579A (en)
ZA (1) ZA796880B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3005845A1 (en) * 1980-02-16 1981-09-03 Boehringer Mannheim Gmbh, 6800 Mannheim AMINO ACID AND PEPTIDESTERS OF LEUKO-INDOANILINES, METHOD FOR THE PRODUCTION THEREOF AND MEANS CONTAINING THESE COMPOUNDS FOR DETECTING PROTEOLYTIC ENZYMS
DE3017721A1 (en) * 1980-05-09 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim AGENT FOR DETECTING ESTEROLYTIC AND / OR PROTEOLYTIC ENZYME AND SUBSTRATES SUITABLE FOR THIS
EP0046742B1 (en) * 1980-08-25 1984-06-27 KabiVitrum AB Peptide substrates for determination of protease activity
US4499185A (en) * 1982-05-17 1985-02-12 Miles Laboratories, Inc. Test for esterase activity in a liquid sample
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4645842A (en) * 1984-04-06 1987-02-24 Miles Laboratories, Inc. Pyrrole compounds for detecting the presence of hydrolytic analytes
US4637979A (en) * 1984-04-06 1987-01-20 Miles Laboratories, Inc. Composition and test device for determining the presence of leukocytes containing a zwitterion coupling agent
IL73998A (en) * 1984-04-06 1988-08-31 Miles Lab Preparation of 3-(n-tosyl-l-alaninyloxy)-pyrrole compounds
US4657855A (en) * 1984-04-06 1987-04-14 Miles Laboratories, Inc. Composition and test device for determining the presence of leukocytes, esterase and protease in a test sample
DE3412939A1 (en) * 1984-04-06 1985-10-17 Behringwerke Ag, 3550 Marburg SUBSTRATES FOR HYDROLASES, METHOD FOR THEIR PRODUCTION AND THEIR USE
US4716236A (en) * 1984-04-06 1987-12-29 Miles Laboratories, Inc. Method for synthesizing esters
DE3413077A1 (en) * 1984-04-06 1985-10-17 Miles Laboratories, Inc., Elkhart, Ind. CHROMOGENEIC AMINO ACID AND PEPTIDESTERS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE COMPOUNDS IN ANALYZING METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND / OR PROTEOLYTIC ENZYMES
DE3413078A1 (en) * 1984-04-06 1985-10-24 Miles Laboratories, Inc., Elkhart, Ind. CHROMOGENEIC AMINO ACID AND PEPTIDESTERS, METHOD FOR THE PRODUCTION THEREOF, USE OF THESE COMPOUNDS IN ANALYZING METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND / OR PROTEOLYTIC ENZYMES
DE3446714A1 (en) * 1984-12-21 1986-06-26 Boehringer Mannheim Gmbh METHOD FOR DETECTING THE PRESENCE OF AN ALLERGY AND FOR SPECIFIC DETECTING THE ALLERGY RESPONSIBLE FOR THE ALLERGY
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5179112A (en) * 1985-04-17 1993-01-12 Ici Americas Inc. Heterocyclic amide derivatives and pharmaceutical use
EP0227241B1 (en) * 1985-10-17 1996-09-11 Zeneca Inc. Medicinal indole and indazole keto sulphone derivatives
GB8623429D0 (en) * 1985-10-17 1986-11-05 Ici America Inc Carboximide derivatives
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
JP3043063B2 (en) * 1989-04-27 2000-05-22 バイオコントロール システムズ インコーポレイテッド Precipitation test for microorganisms
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates
US5464739A (en) 1994-08-22 1995-11-07 Bayer Corporation Composition method for determining the presence of leukocyte cells, esterase or protease in a test sample
CA2161574A1 (en) 1994-11-15 1996-05-16 James Noffsinger Methodology for colorimetrically determining the concentration of white blood cells in a biological fluid
FR2751663B1 (en) * 1996-07-29 1998-10-02 Bio Merieux METHOD FOR EVIDENCE OF AN ENZYMATIC ACTIVITY OF MICROORGANISMS
DE19651886A1 (en) * 1996-12-13 1998-06-18 Merck Patent Gmbh Means and methods for the determination of hydrolytic enzymes
GB2326712B (en) * 1997-06-25 2001-09-26 Fujirebio Kk Colour devoloping method,enzyme immunoassay using the colour developing method,and immunochromatography incorporating the enzyme immunoassay
DE19735614A1 (en) * 1997-08-16 1999-02-18 Lothar Dr Seik Detection of protease activity for insulin-like growth factor binding proteins
DE19829707C2 (en) * 1998-07-03 2002-07-18 Macherey Nagel Gmbh & Co Hg Diagnostic agent for the detection of leukocytes, elastases, esterases and proteases
US6528652B1 (en) * 1999-01-21 2003-03-04 Chronimed Composition and device for detecting leukocytes in urine
US6348324B1 (en) 1999-01-21 2002-02-19 Hypoguard America Limited Composition and device for detecting leukocytes in urine
US6709868B2 (en) * 2002-05-20 2004-03-23 Portascience Inc. Method and apparatus for measuring white blood cell count
EP1869457B1 (en) * 2004-12-13 2011-10-26 Bayer HealthCare LLC A method of differentiating between blood and control solutions containing a common analyte
GB2426334A (en) * 2005-05-20 2006-11-22 Orion Diagnostica Oy Application of a reagent to a matrix material
US7504235B2 (en) * 2005-08-31 2009-03-17 Kimberly-Clark Worldwide, Inc. Enzyme detection technique
US7727206B2 (en) * 2005-12-27 2010-06-01 Gorres Geoffrey H Device for monitoring a patient for a urinary tract infection
US9103796B2 (en) 2007-12-14 2015-08-11 Kimberly-Clark Worldwide, Inc. Multi-layered devices for analyte detection
US11104933B1 (en) * 2016-03-22 2021-08-31 Cleu Diagnostics, Llc Compositions and methods for determining the presence of active leukocyte cells using an electrochemical assay

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3087794A (en) 1960-05-23 1963-04-30 Miles Lab Chemical test for differentiating leucocytes from erythrocytes
BE615395A (en) * 1962-03-21
GB1128371A (en) 1965-10-04 1968-09-25 Miles Lab Diagnostic composition
DE2118455B1 (en) 1971-04-16 1972-09-21 Boehringer Mannheim Gmbh Test strips
US4061625A (en) * 1975-07-11 1977-12-06 Ab Kabi Novel chromogenic thrombin substrates
JPS5263794A (en) * 1975-11-21 1977-05-26 Shionogi Seiyaku Kk Test piece for latent blood
JPS53132539A (en) * 1977-04-22 1978-11-18 Takeda Chem Ind Ltd Protected amino acid or peptide having said protected amino acid residue
JPS53147034A (en) * 1977-05-30 1978-12-21 Wako Pure Chem Ind Ltd Gamma-glutamyl-p-aminoanilide derivatives and process for their preparation
US4216142A (en) * 1978-12-18 1980-08-05 Abbott Laboratories Chromogenic substrates for the proteolytic enzymes

Also Published As

Publication number Publication date
DK155318C (en) 1989-08-28
PL220526A1 (en) 1980-12-01
DE2960857D1 (en) 1981-12-03
EP0012957A1 (en) 1980-07-09
CS245763B2 (en) 1986-10-16
SU1184444A3 (en) 1985-10-07
DK155318B (en) 1989-03-28
AR223505A1 (en) 1981-08-31
AU5383879A (en) 1980-06-26
CA1130801A (en) 1982-08-31
HU180431B (en) 1983-03-28
ES486932A1 (en) 1980-05-16
YU311579A (en) 1984-04-30
AU515190B2 (en) 1981-03-19
ZA796880B (en) 1980-12-31
FI77229B (en) 1988-10-31
PT70608A (en) 1980-01-01
SU1156595A3 (en) 1985-05-15
DE2854987A1 (en) 1980-06-26
JPS5585561A (en) 1980-06-27
JPS593475B2 (en) 1984-01-24
PL127198B1 (en) 1983-10-31
US4278763A (en) 1981-07-14
BR7908306A (en) 1980-09-09
DK535679A (en) 1980-06-21
FI793986A (en) 1980-06-21
DD147845A5 (en) 1981-04-22
FI77229C (en) 1989-02-10
ATE230T1 (en) 1981-10-15

Similar Documents

Publication Publication Date Title
EP0012957B1 (en) Diagnostic means for the detection of proteolytic enzymes and indoxyl or thioindoxyl ester chromogens useful therefor, process for their preparation and their use in the preparation of diagnostic means
EP0039880B2 (en) Agents for the detection of esterolytic and/or proteolytic enzymes; and phenoxy-amino acids and phenoxy-peptide esters suitable as substrates therefor, process for their production and their use in producing the agents
EP0157360B1 (en) Chromogenic esters of amino acids and peptides, processes for their preparation, use of these agents in methods of analysis and agents for detection of esterolytic and/or proteolytic enzymes
EP0157384B1 (en) Substrates for hydrolases, process for their preparation and their use
DE3331588C2 (en)
EP0157362A2 (en) Chromogenic amino acids and peptide esters, process for their preparation, use of these compounds in analytical processes, as well as agents for marking esterolytic and/or proteolytic enzymes
EP0007407B1 (en) Diagnostic composition for the detection of leukocytes in body fluids, sulfophthalein esters as chromogens used for this composition, method of their preparation and their use for preparing diagnostic compositions
EP0008428B1 (en) Diagnostic reagent for the detection of leukocytes in body fluids and azo-ester dyes useful as chromogens therefor, process for their preparation and their use in the preparation of diagnostic reagents for the detection of leukocytes in body fluids
EP0034323B1 (en) Amino acid and peptide esters of leuco-indo anilines, process for their preparation and agents containing these compounds for the detection of proteolytic enzymes
EP0158225A2 (en) Analysis method and means for detecting esterolytic and/or proteolytic enzymes
DE3644401A1 (en) NEW HYDROLASE SUBSTRATES
EP0019589A1 (en) Tripeptide derivatives and their use in a process for determining enzymes
EP0433855B1 (en) N- and O-substituted aminophenol derivatives, intermediates for their preparation, their use as hydrolase substrates, a corresponding assay and diagnostic agents
EP0190299A1 (en) NEW p-PHENYLENEDIAMINE PEPTIDES AND REACTANCE CONTAINING THEM FOR THE DETERMINATION OF PROTEASES OF THE BLOOD COAGULATION SYSTEM
EP0217371A2 (en) Phosphates of resorufin derivatives, process for their preparation and their use in the determination of the activity of phosphatases
EP0158224B1 (en) Analysis method and means for detecting esterolytic and/or proteolytic enzymes
EP0004589B1 (en) Alpha-n-acetyl-l-phenylalanine-l-arginine-ethyl ester, process for its preparation and its use as a diagnostic agent for kallikrein
EP0157361B1 (en) Analysis method and means for detecting esterolytic and or proteolytic enzymes
DE3136511A1 (en) LEUCYLALANYLARGINE IN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

17P Request for examination filed
ITF It: translation for a ep patent filed

Owner name: ING. C. GREGORJ S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

REF Corresponds to:

Ref document number: 230

Country of ref document: AT

Date of ref document: 19811015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 2960857

Country of ref document: DE

Date of ref document: 19811203

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: MILES LABORATORIES, INC.

Effective date: 19820616

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 19841115

NLR2 Nl: decision of opposition
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 79105184.0

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19981207

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19981209

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19981214

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19981218

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19981221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19981223

Year of fee payment: 20

Ref country code: CH

Payment date: 19981223

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19981229

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 19991214 *BOEHRINGER MANNHEIM G.M.B.H.

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19990215

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19991213

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19991213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19991214

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19991214

Ref country code: AT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 19991214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991230

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 19991213

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 19991214

EUG Se: european patent has lapsed

Ref document number: 79105184.0